<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 201905//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxins (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Toxins (Basel)</journal-id><journal-id journal-id-type="publisher-id">toxins</journal-id><journal-title-group><journal-title>Toxins</journal-title></journal-title-group><issn pub-type="epub">2072-6651</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8151066</article-id><article-id pub-id-type="pmid">34065799</article-id><article-id pub-id-type="doi">10.3390/toxins13050346</article-id><article-id pub-id-type="publisher-id">toxins-13-00346</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Shining a Light on Colibactin Biology</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3774-7912</contrib-id><name><surname>Dougherty</surname><given-names>Michael W.</given-names></name><xref ref-type="aff" rid="af1-toxins-13-00346">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3733-1001</contrib-id><name><surname>Jobin</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="af1-toxins-13-00346">1</xref><xref ref-type="aff" rid="af2-toxins-13-00346">2</xref><xref rid="c1-toxins-13-00346" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-toxins-13-00346"><label>1</label>Department of Medicine, University of Florida, Gainesville, FL 32610, USA; <email>Michael.dougherty@medicine.ufl.edu</email></aff><aff id="af2-toxins-13-00346"><label>2</label>Department of Infectious Diseases and Inflammation, University of Florida, Gainesville, FL 32610, USA</aff><author-notes><corresp id="c1-toxins-13-00346"><label>*</label>Correspondence: <email>Christian.jobin@medicine.ufl.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>5</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2021</year></pub-date><volume>13</volume><issue>5</issue><elocation-id>346</elocation-id><history><date date-type="received"><day>06</day><month>4</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Colibactin is a secondary metabolite encoded by the <italic>pks</italic> gene island identified in several Enterobacteriaceae, including some pathogenic <italic>Escherichia coli</italic> (<italic>E. coli</italic>) commonly enriched in mucosal tissue collected from patients with inflammatory bowel disease and colorectal cancer. <italic>E. coli</italic> harboring this biosynthetic gene cluster cause DNA damage and tumorigenesis in cell lines and pre-clinical models, yet fundamental knowledge regarding colibactin function is lacking. To accurately assess the role of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> in cancer etiology, the biological mechanisms governing production and delivery of colibactin by these bacteria must be elucidated. In this review, we will focus on recent advances in our understanding of colibactin&#x02019;s structural mode-of-action and mutagenic potential with consideration for how this activity may be regulated by physiologic conditions within the intestine. </p></abstract><kwd-group><kwd>colibactin</kwd><kwd>genotoxin</kwd><kwd><italic>pks</italic></kwd><kwd><italic>Escherichia coli</italic></kwd><kwd>colorectal cancer</kwd><kwd>DNA damage</kwd><kwd>mutation</kwd><kwd>microbiome</kwd><kwd>inflammation</kwd><kwd><italic>APC</italic></kwd></kwd-group></article-meta><notes notes-type="Key Contribution"><title>Key Contribution</title><p>Colibactin is a potential carcinogenic metabolite produced by <italic>pks<sup>+</sup> E. coli</italic> and few other Enterobacteriaceae. Complex biological and cellular events influence <italic>pks<sup>+</sup> E. coli</italic>-derived genotoxicity and, consequently, carcinogenesis.</p></notes></front><body><sec sec-type="intro" id="sec1-toxins-13-00346"><title>1. Introduction</title><p><italic>Escherichia coli (E. coli</italic>) are a group of Gram-negative facultative anaerobic bacteria isolated from multiple body sites of almost every individual, paradoxically implicated in both intestinal homeostasis and various pathologies depending on species and subspecies classification [<xref rid="B1-toxins-13-00346" ref-type="bibr">1</xref>]. Certain <italic>E. coli</italic> strains, primarily from the B2-phylogroup, harbor a pathogenic island termed <italic>pks</italic>. This biosynthetic gene cluster is widely distributed throughout various Enterobacteriaceae and encodes for a secondary metabolite named colibactin, putatively acquired through horizontal gene transfer as part of a mobile genetic element [<xref rid="B2-toxins-13-00346" ref-type="bibr">2</xref>]. The widespread distribution, prevalence, and evolutionary persistence of <italic>pks</italic> genes in this bacterial family suggest that this biosynthetic gene cluster may promote host fitness. In contrast, these compounds have deleterious effects in eukaryotic cells, inhibiting cell-cycle progression and inducing DNA damage [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>,<xref rid="B4-toxins-13-00346" ref-type="bibr">4</xref>]. Recently, the structure of colibactin has been identified [<xref rid="B5-toxins-13-00346" ref-type="bibr">5</xref>]. Colibactin contains dual electrophilic warheads each capable of binding DNA, suggesting that colibactin causes DNA damage by inducing interstrand DNA-crosslinks [<xref rid="B5-toxins-13-00346" ref-type="bibr">5</xref>,<xref rid="B6-toxins-13-00346" ref-type="bibr">6</xref>,<xref rid="B7-toxins-13-00346" ref-type="bibr">7</xref>].</p><p>The production of a genotoxic cyclomodulin by a common commensal microbe (<italic>E. coli</italic>) led to the hypothesis that these microbes may play a causative role in a subset of colorectal cancer (CRC) cases, as exposure to environmental genotoxins may promote specific somatic mutations implicated in a variety of cancers [<xref rid="B8-toxins-13-00346" ref-type="bibr">8</xref>]. In murine models of colitis-associated cancer, administration of <italic>pks<sup>+</sup> E. coli</italic> promotes tumor formation [<xref rid="B4-toxins-13-00346" ref-type="bibr">4</xref>]. Furthermore, <italic>pks<sup>+</sup> E. coli</italic> are identified in tumor biopsies from CRC (66.7%) and IBD cases (40%) at a higher rate than healthy individuals (20.8%) [<xref rid="B4-toxins-13-00346" ref-type="bibr">4</xref>]. Subsequent studies utilizing in vitro models ascertained a unique mutational signature occurring after exposure to <italic>pks<sup>+</sup> E. coli</italic> consistent with the hypothesized nucleotide binding activity of the recently proposed colibactin structure, and identified these mutational signatures in approximately 5% of colorectal cancer patients [<xref rid="B9-toxins-13-00346" ref-type="bibr">9</xref>]. Collectively, these studies have generated a high amount of research aimed at elucidating colibactin&#x02019;s mutagenic potential in the context of CRC etiology. However, colibactin itself is a highly unstable molecule and cancer development is dependent on specific biological context, leading to some debate regarding its role as an initiator of tumorigenesis [<xref rid="B10-toxins-13-00346" ref-type="bibr">10</xref>]. Thus, a number of recent studies have focused on identifying how colibactin regulation and <italic>pks</italic><sup>+</sup>
<italic>E. coli</italic> biology may influence the oncogenic capacity of the compound [<xref rid="B11-toxins-13-00346" ref-type="bibr">11</xref>,<xref rid="B12-toxins-13-00346" ref-type="bibr">12</xref>,<xref rid="B13-toxins-13-00346" ref-type="bibr">13</xref>,<xref rid="B14-toxins-13-00346" ref-type="bibr">14</xref>,<xref rid="B15-toxins-13-00346" ref-type="bibr">15</xref>,<xref rid="B16-toxins-13-00346" ref-type="bibr">16</xref>]. In this review, we will summarize how advances in our understanding of colibactin&#x02019;s structural mode-of-action have begun to clarify the role <italic>pks<sup>+</sup> E. coli</italic> may play in CRC, and how new findings describing <italic>pks</italic> regulation shed a light on how physiologic contexts may influence its carcinogenic potential. </p></sec><sec id="sec2-toxins-13-00346"><title>2. Colibactin Genotoxicity</title><p>Bacterial genotoxins are secondary metabolites which directly damage host DNA. Such compounds have the potential to trigger genomic instability, as cells with deficiencies in DNA repair pathways or are utilizing error-prone repair pathways have a high risk of mutational acquisition following exposure to genotoxic stressors in their environment [<xref rid="B17-toxins-13-00346" ref-type="bibr">17</xref>]. Because genetic mutations are a hallmark of almost all cancers [<xref rid="B18-toxins-13-00346" ref-type="bibr">18</xref>] and <italic>pks<sup>+</sup> E. coli</italic> promote tumor formation in pre-clinical models [<xref rid="B4-toxins-13-00346" ref-type="bibr">4</xref>], it is reasonable to theorize that colonization by microbes producing colibactin may be linked to higher cancer risk. However, until recently colibactin&#x02019;s mode-of-action remained unclear. In this section, we will review how recent advances in structural characterization of this compound have helped elucidate the mutagenic potential of <italic>pks<sup>+</sup> E. coli,</italic> providing a putative mechanism for carcinogenic phenotypes observed nearly a decade earlier. </p><sec id="sec2dot1-toxins-13-00346"><title>2.1. Structure and Alkylating Activity</title><p>Colibactin is a secondary metabolite produced by the 54-kb <italic>pks</italic> gene island encoding for a hybrid non-ribosomal peptide synthetase (NRPS)&#x02014;polyketide synthetase (PKS) assembly line and accessory proteins (<italic>clbA&#x02014;S</italic>; <xref ref-type="fig" rid="toxins-13-00346-f001">Figure 1</xref>) [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>]. This NRPS-PKS protein assembly produces linear biosynthetic intermediates termed precolibactin which are characterized by a <italic>N</italic>-myristoyl-D-Asn prodrug motif (<xref ref-type="fig" rid="toxins-13-00346-f001">Figure 1</xref>). Precolibactins are translocated into the periplasm via the multi-drug and toxin extrusion transporter ClbM [<xref rid="B19-toxins-13-00346" ref-type="bibr">19</xref>] and then converted to genotoxic colibactin through the removal of prodrug motifs via the membrane-bound peptidase ClbP [<xref rid="B20-toxins-13-00346" ref-type="bibr">20</xref>]. Removal of prodrug motifs causes spontaneous four-fold cyclization of linear precolibactins to yield the bioactive colibactin structure (<xref ref-type="fig" rid="toxins-13-00346-f001">Figure 1</xref>) [<xref rid="B21-toxins-13-00346" ref-type="bibr">21</xref>]. Colibactin is composed of two nearly symmetrical subunits, each containing an electrophilic cyclopropane warhead which binds adenine residues on DNA to generate interstrand cross-links (<xref ref-type="fig" rid="toxins-13-00346-f001">Figure 1</xref>) [<xref rid="B5-toxins-13-00346" ref-type="bibr">5</xref>,<xref rid="B21-toxins-13-00346" ref-type="bibr">21</xref>,<xref rid="B22-toxins-13-00346" ref-type="bibr">22</xref>]. The incorporation of prodrug motifs in colibactin biosynthesis may be part of a self-resistance mechanism common to toxin biosynthesis pathways in multiple bacterial species [<xref rid="B20-toxins-13-00346" ref-type="bibr">20</xref>]. However, studies utilizing <italic>clbP</italic> mutants to characterize various shunt precolibactins demonstrated that a subset of these molecules, in the presence of copper, generate interstrand cross-links (ICLs) in linearized plasmid DNA [<xref rid="B7-toxins-13-00346" ref-type="bibr">7</xref>], a phenomena still not fully understood. For several years, colibactin&#x02019;s structure and mode-of-action remained elusive due to its resilience to traditional isolation techniques and high instability. Recent studies have utilized DNA-adducts formed during exposure of <italic>pks</italic><sup>+</sup> bacteria to linearized plasmids [<xref rid="B5-toxins-13-00346" ref-type="bibr">5</xref>] or within gnotobiotic mice [<xref rid="B22-toxins-13-00346" ref-type="bibr">22</xref>] to characterize the structure of DNA-bound colibactin, providing the first insight into colibactin&#x02019;s molecular structure and identifying DNA-reactive electrophilic sites capable of alkylating DNA by ring-opening addition [<xref rid="B5-toxins-13-00346" ref-type="bibr">5</xref>]. <italic>In silico</italic> modeling utilizing structures derived from adductomics suggest colibactin has a high binding affinity for adenine rich motifs (AAAATT) within the DNA minor groove [<xref rid="B23-toxins-13-00346" ref-type="bibr">23</xref>]. These findings support colibactin&#x02019;s proposed activity as a DNA cross-linking agent and have helped clarify the molecular mechanisms of colibactin-associated genotoxicity. The next section will address mammalian host response mechanisms associated with <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> exposure.</p></sec><sec id="sec2dot2-toxins-13-00346"><title>2.2. Genotoxic Activity in Mammalian Cells</title><p>Several studies have demonstrated the genotoxic property of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E.</italic>&#x000a0;<italic>coli</italic> and have identified signaling pathways associated with this cellular response. For example, <italic>E. coli</italic> harboring a bacterial artificial chromosome encoding the complete <italic>pks</italic> gene island (BAC<sub>pks</sub>) activate classical ataxia telangiectasia (ATM) and Rad53 related (ATR) dependent DNA damage responses (DDR) in infected HeLa cells, characterized by phosphorylation of checkpoint kinase 2 (CHK2), replication protein A (RPA), &#x003b3;H2AX, and the accumulation of phosphorylated cyclin dependent kinase 1 (CDC2) resulting in G2-cell cycle arrest (<xref ref-type="fig" rid="toxins-13-00346-f002">Figure 2</xref>) [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>]. <italic>Pks</italic>-induced DDR activation in HeLa cells promotes recruitment of the interstrand cross-link (ICL) repair protein FANCD2 to phosphorylated &#x003b3;H2AX sites [<xref rid="B6-toxins-13-00346" ref-type="bibr">6</xref>], suggesting involvement of the Fanconi-anemia (FA) pathway in repairing colibactin-generated ICLs. While these results are consistent with colibactin&#x02019;s proposed alkylating activity, several other studies suggest infection with <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> also induces double-strand breaks (DSBs), which can be directly visualized by neutral comet assay after infection [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>]. In CHO cells, exposure to <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> causes increased recruitment of the non-homologous end joining repair protein Ku80 [<xref rid="B24-toxins-13-00346" ref-type="bibr">24</xref>], a pathway primarily involved in the resolution of DSBs rather than ICLs. Structural elucidation of colibactin implies that the compound is likely not involved in the direct formation of DSBs, suggesting that DNA breaks may instead be the product of endogenous changes occurring after the formation of alkylated lesions generated by colibactin-mediated cross-linking. Activation of FA pathways may indirectly cause DSBs, as cells excise cross-linked DNA using homologous cellular pathways (e.g., &#x003b3;H2AX) before undergoing repair [<xref rid="B25-toxins-13-00346" ref-type="bibr">25</xref>]. Alternatively, the internalization of certain <italic>pks</italic><sup>+</sup> adherent invasive <italic>E. coli</italic> (AIEC) strains may promote the production of reactive oxygen species (ROS) which cause DSBs [<xref rid="B26-toxins-13-00346" ref-type="bibr">26</xref>] expected to trigger the apurinic/apyrimidinic endonuclease system (APE1). It is unclear if ROS production is dependent on <italic>pks</italic> or simply a response to bacterial internalization which may exacerbate DNA damage caused by colibactin.</p><p>Perhaps the most cryptic aspect of colibactin&#x02019;s genotoxic mechanisms is the method by which these molecules translocate from the bacterial periplasm to the host nucleus (<xref ref-type="fig" rid="toxins-13-00346-f002">Figure 2</xref>). It is known that cell-to-cell contact is necessary for genotoxicity after <italic>pks</italic><sup>+</sup> infection in vitro, as separation of mammalian cells and bacteria by cell-impermeable membranes attenuates colibactin&#x02019;s cytotoxic effects [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>]. It seems likely that the compounds instability may prevent remote delivery by pathogenic bacteria but remains unclear if specific secretion systems are necessary to deliver colibactin to host cells. So far, no essential transporters for <italic>pks</italic><sup>+</sup> genotoxicity have been identified. Interestingly, early experiments inhibiting bacterial internalization did not attenuate BAC<sub>pks</sub> genotoxicity [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>]. In contrast, a clinical <italic>pks</italic><sup>+</sup> AIEC isolate from a CRC patient was shown to invade and replicate within epithelial cells, with a concomitant increase in tumor formation [<xref rid="B27-toxins-13-00346" ref-type="bibr">27</xref>]. In murine models administered this strain, oncogenic activity could be attenuated by either effective host autophagy or mutation of the <italic>pks</italic> editing thioesterase <italic>clbQ</italic> required for colibactin production [<xref rid="B27-toxins-13-00346" ref-type="bibr">27</xref>], suggesting a potential association between intracellular invasion and <italic>pks</italic><sup>+</sup> AIEC&#x02019;s tumorigenic efficacy. However, it remains unclear if this internalization enhances colibactin&#x02019;s effects or is simply a byproduct of lowered host defense (in this case, genetically modified autophagy-deficient mice) while autophagy promotes DDR through a different mechanism. Since release of bacterial outer member vesicles have been linked to DNA damage [<xref rid="B28-toxins-13-00346" ref-type="bibr">28</xref>], it would be interesting to investigate this mode of bacterial-host communication in <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> mediated genotoxicity.</p></sec><sec id="sec2dot3-toxins-13-00346"><title>2.3. Pks-Induced Mutagenesis</title><p>In mammalian cells, exposure to <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> leads to the accumulation of chromosomal aberrations and aneuploidy, suggesting colibactin exposure may be linked to oncogenic mutation [<xref rid="B24-toxins-13-00346" ref-type="bibr">24</xref>]. Acute exposure of human colonic organoids to <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> induces functional mutations related to the p53 and Wnt signaling pathways [<xref rid="B29-toxins-13-00346" ref-type="bibr">29</xref>]. Importantly, colonic organoid cultures continue to proliferate in the absence of the traditionally essential growth factors Wnt3a and CHIR99021, both regulators of the adenomatous polyposis coli (<italic>APC</italic>) signaling pathways mutated in 80% of CRC cases [<xref rid="B29-toxins-13-00346" ref-type="bibr">29</xref>]. These derived Wnt-independent cultures expressed higher stem-cell transcriptional signatures (e.g., Lgr5, Fzd7, Sox9) and avoided p53-mediated apoptosis following administration of the p53 pathway activator Nutlin-3a, providing direct evidence of oncogenic mutation following <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> infection (<xref ref-type="fig" rid="toxins-13-00346-f002">Figure 2</xref>) [<xref rid="B29-toxins-13-00346" ref-type="bibr">29</xref>]. Two independent groups identified mutational signatures arising from <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> infection in vitro [<xref rid="B9-toxins-13-00346" ref-type="bibr">9</xref>,<xref rid="B23-toxins-13-00346" ref-type="bibr">23</xref>]. Pleguezuelos-Manazno, Puschhof, and Huber et al. [<xref rid="B9-toxins-13-00346" ref-type="bibr">9</xref>] performed whole-genome sequencing of clonal organoids after chronic exposure to <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic>. These investigators identified a mutational signature characterized by a high number of single-base substitutions (SBS-<italic>pks</italic>, T &#x0003e; N) and less common short insertion-deletions (ID-<italic>pks</italic>) within AT-rich DNA regions. Similarly, Dziubanska-Kusibab et al. [<xref rid="B23-toxins-13-00346" ref-type="bibr">23</xref>] demonstrated specific enrichment of SBSs within AT-rich pentanucleotide sequences located in the DNA minor groove following short-term exposure of Caco-2 cells to <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic>. During chronic infection, a majority of SBS-<italic>pks</italic> motifs occurred within the coding DNA strand and mutations matching either SBS-<italic>pks</italic> and ID-<italic>pks</italic> motifs were identified in 5% and 4.4%, respectively, of CRC tumors from an independent database of 2208 predominately primary sites [<xref rid="B9-toxins-13-00346" ref-type="bibr">9</xref>]. In these cases the gene with the highest number of mutations matching the <italic>pks</italic>-target motif was the <italic>APC</italic> gene (5.3%), which is frequently mutated in CRC cases [<xref rid="B9-toxins-13-00346" ref-type="bibr">9</xref>]. Interestingly, the incidence of SBS/ID-<italic>pks</italic> motifs in CRC cases is much lower than the incidence of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> identified from colorectal tumors (67% [<xref rid="B4-toxins-13-00346" ref-type="bibr">4</xref>]), further implying that the carcinogenic capacity of these microbes is derived from the combinatory production of colibactin and other aspects of intestinal ecology (see commentary [<xref rid="B30-toxins-13-00346" ref-type="bibr">30</xref>]). Collectively, these findings provide direct evidence of the mutagenic potential of colibactin in the context of CRC (<xref ref-type="fig" rid="toxins-13-00346-f002">Figure 2</xref>). Importantly, presence of <italic>pks</italic><sup>+</sup> bacteria alone is likely insufficient for cancer development, and the colibactin mutational signature is found in a large number of healthy individuals as well as CRC patients [<xref rid="B31-toxins-13-00346" ref-type="bibr">31</xref>], suggesting typically commensal <italic>pks</italic><sup>+</sup> bacteria may only exert a carcinogenic influence under specific conditions.</p></sec></sec><sec id="sec3-toxins-13-00346"><title>3. Colibactin Activity in Physiologic Context</title><p>In order to exert a mutagenic influence on the host epithelium in vivo, experimental evidence suggests <italic>pks<sup>+</sup> E. coli</italic> likely requires two physiologic factors, namely: (1) transcriptional activation of all <italic>clb</italic> genes (besides <italic>clbS</italic>), and (2) cell-to-cell contact, i.e., a close association between colonizing <italic>pks<sup>+</sup></italic> strains and host epithelial cells [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>]. Bacterial metabolism and biosynthesis of specific compounds is regulated through transcriptional mechanisms influenced by metabolic conditions in the environment [<xref rid="B32-toxins-13-00346" ref-type="bibr">32</xref>,<xref rid="B33-toxins-13-00346" ref-type="bibr">33</xref>,<xref rid="B34-toxins-13-00346" ref-type="bibr">34</xref>]. Thus, an understanding of how <italic>pks<sup>+</sup> E. coli</italic> regulate colibactin with respect to environmental condition, particularly during opportunistic expansion near the host epithelium, is critical to assessing the carcinogenic potential of these bacteria. In this section, we will summarize the current framework of colibactin regulation and how its genotoxic potential may be functionally influenced by environmental condition. Finally, we will summarize a newly emerging research area focused on characterizing colibactin&#x02019;s effects extending beyond direct DNA damage.</p><sec id="sec3dot1-toxins-13-00346"><title>3.1. Metabolic Regulation of pks Genes</title><p>The <italic>pks</italic> operon consists of four polycistronic transcripts (of seven total) oriented in a single direction, with the exception being a single polycistron encoding the pantetheinyltransferase (PPTase) (<italic>clbA</italic>) and the LuxR-type transcriptional activator (<italic>clbR</italic>) (<xref ref-type="fig" rid="toxins-13-00346-f001">Figure 1</xref>) [<xref rid="B35-toxins-13-00346" ref-type="bibr">35</xref>] that promote the expression of downstream <italic>pks</italic> genes [<xref rid="B11-toxins-13-00346" ref-type="bibr">11</xref>]. Transcription of these regulatory elements may govern colibactin production, and their expression levels are directly influenced by environmental metabolites (<xref ref-type="fig" rid="toxins-13-00346-f003">Figure 3</xref>a). With respect to the dominant intestinal taxa (e.g., Bacteroidetes, Firmicutes), <italic>E. coli</italic> have relatively limited glycolytic capacity, instead relying on an abundant siderophoric repertoire to opportunistically thrive in iron-limited conditions [<xref rid="B36-toxins-13-00346" ref-type="bibr">36</xref>]. These pathways are controlled by the ferric iron uptake regulator (Fur) that is activated in low-iron conditions and binds directly to the promoter region of the <italic>pks</italic> gene <italic>clbA</italic> [<xref rid="B15-toxins-13-00346" ref-type="bibr">15</xref>], which in turn acts as both an additional siderophore and an initiator of colibactin biosynthesis [<xref rid="B16-toxins-13-00346" ref-type="bibr">16</xref>]. The regulatory <italic>pks</italic> gene <italic>clbR</italic>, which acts as a transcription factor for <italic>clbB</italic>, is similarly upregulated in low iron conditions [<xref rid="B11-toxins-13-00346" ref-type="bibr">11</xref>]. As expected given these findings, when <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> are cultured in high-iron conditions production of colibactin is inhibited [<xref rid="B12-toxins-13-00346" ref-type="bibr">12</xref>]. Additionally, the colibactin transmembrane peptidase ClbP is required for production of the siderophore microcin in <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> Nissle 1917 (EcN), and is necessary for colonization in the presence of other opportunistic pathogens such as <italic>Salmonella</italic> Typhimurium [<xref rid="B13-toxins-13-00346" ref-type="bibr">13</xref>]. Thus, <italic>pks</italic> genes may provide an evolutionary advantage to <italic>E. coli</italic> strains by enhancing iron-scavenging capabilities by acting as or contributing to the maturation of critical siderophores. </p><p>Other metabolites derived endogenously from <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> or the host diet similarly alter transcription of <italic>clb</italic> genes. Spermidine, a polyamine produced during bacterial metabolism or scavenged from the environment is necessary for the production of colibactin [<xref rid="B14-toxins-13-00346" ref-type="bibr">14</xref>]. Administration of oligosaccharide prebiotics, such as inulin or glucose, similarly enhance <italic>clbA</italic> transcription and <italic>pks</italic><sup>+</sup> genotoxicity [<xref rid="B37-toxins-13-00346" ref-type="bibr">37</xref>]. In contrast, metabolites promoting <italic>pks</italic> transcription can be attenuated by inhibitory factors (such as ferrous sulfate [<xref rid="B37-toxins-13-00346" ref-type="bibr">37</xref>]), suggesting that regulation of colibactin production is thus intrinsically linked to metabolic conditions within the intestinal lumen or the mucosal lining. These findings are particularly relevant when considering how the carcinogenic activity of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> may be enhanced in colitis or CRC patients, who often present with anemia [<xref rid="B38-toxins-13-00346" ref-type="bibr">38</xref>] or other disruptions to metabolic homeostasis which may alter <italic>pks</italic> transcription. However, since direct measurement of colibactin level is currently unavailable, the consequences of transcriptional changes in individual <italic>pks</italic> genes on cellular genotoxicity in vivo is unclear.</p></sec><sec id="sec3dot2-toxins-13-00346"><title>3.2. Inflammation</title><p>Inflammatory bowel disease (IBD) creates a pro-neoplastic environment within the colonic epithelium [<xref rid="B39-toxins-13-00346" ref-type="bibr">39</xref>] that promotes dysplasia and the development of colitis-associated cancer (CAC) [<xref rid="B40-toxins-13-00346" ref-type="bibr">40</xref>]. Inflammation heavily modulates microbial balance in the gut, typically associated with increased Proteobacteria/Enterobacteriaceae/<italic>E. coli</italic> prevalence. For example, chemically-induced inflammation following dextran sodium sulfate (DSS) treatment reduces populations of anaerobic Bacteroidetes by approximately 70% while increasing levels of various aerobic species by approximately 25% [<xref rid="B41-toxins-13-00346" ref-type="bibr">41</xref>]. In this acute model, the abundance of a nonpathogenic <italic>E. coli</italic> strain doubled in DSS treated mice, and colonization in <italic>E. coli</italic>-na&#x000ef;ve mice corresponded with a decrease in mucosal Bacteroidales colonization [<xref rid="B41-toxins-13-00346" ref-type="bibr">41</xref>]. Several epidemiological studies have established a link between IBD or CRC and increased mucosal colonization by <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli,</italic> accounting for as much as 13% (IBD) or 26% (CRC) of all <italic>E. coli</italic> strains isolated from these patients [<xref rid="B4-toxins-13-00346" ref-type="bibr">4</xref>,<xref rid="B42-toxins-13-00346" ref-type="bibr">42</xref>,<xref rid="B43-toxins-13-00346" ref-type="bibr">43</xref>]. These findings suggest tumorigenesis may be driven, at least partially, by selective enrichment of <italic>pks</italic><sup>+</sup> strains within the colonic mucosa. This hypothesis is borne out by studies in murine models of CAC utilizing azoxymethane treated <italic>Il10<sup>&#x02212;/&#x02212;</sup></italic> mice, showing that the presence of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> promotes DNA damage and neoplastic transformation under inflammatory conditions [<xref rid="B4-toxins-13-00346" ref-type="bibr">4</xref>] abrogated in Rag2<sup>&#x02212;/&#x02212;</sup> mice with no inflammatory response [<xref rid="B44-toxins-13-00346" ref-type="bibr">44</xref>]. In similar models of CAC, limiting <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> colonization during inflammation by inhibiting nitrate reductase activity abrogates <italic>pks</italic>-associated tumorigenesis [<xref rid="B45-toxins-13-00346" ref-type="bibr">45</xref>]. However, the current clinical impracticality of eradicating <italic>E. coli</italic> populations in colitis patients renders this an unlikely preventative treatment option to limit tumor progression in IBD patient.</p><p>Alternatively, elevated <italic>pks</italic> expression in inflamed tissue may be attenuated as a byproduct of IBD treatments which dampen inflammatory cascades or directly inhibit <italic>clb</italic> gene transcription. In murine CAC models gavaged with <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic>, inflammation promotes transcription of multiple <italic>clb</italic> genes involved in colibactin biosynthesis during tumor initiation [<xref rid="B44-toxins-13-00346" ref-type="bibr">44</xref>]. A recent study by Yang et al. [<xref rid="B46-toxins-13-00346" ref-type="bibr">46</xref>] demonstrates that anti-TNF treatment prevents colonic inflammation and subsequent tumor development in both chemically-induced (DSS/<italic>Apc<sup>Min/+</sup></italic>) and spontaneous (<italic>Il10<sup>&#x02212;/&#x02212;</sup> Apc<sup>Min/+</sup></italic>) CAC models by modulating microbiota composition and transcription, while co-housing anti-TNF treated with control mice prevented these microbial change and inhibited the anti-tumor effects of TNF neutralization [<xref rid="B38-toxins-13-00346" ref-type="bibr">38</xref>]. Interestingly, targeting inflammation with anti-TNF antibody did not alter <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> colonization level, pointing to a change in microbial activity [<xref rid="B46-toxins-13-00346" ref-type="bibr">46</xref>]. Related to this, the anti-inflammatory drug mesalamine inhibits the microbial enzyme polyphosphate kinase (PPK), sensitizing bacteria to oxidative stress and inhibiting proliferation <italic>in vitro</italic> [<xref rid="B47-toxins-13-00346" ref-type="bibr">47</xref>]. In a small cohort of human test subjects, mesalamine reduced microbial polyP accumulation, suggesting PPK inhibition reduces microbial metabolism in a clinical setting [<xref rid="B47-toxins-13-00346" ref-type="bibr">47</xref>]. One would expect that these effects would extend to virulence associated with <italic>pks<sup>+</sup> E. coli</italic>, and the evidence suggests mesalamine directly inhibits colibactin production and ICL formation in vitro [<xref rid="B48-toxins-13-00346" ref-type="bibr">48</xref>]. These studies suggests that anti-inflammatory treatment may limit the risk of CRC by acting on the host to limit inflammation-induced dysplasia while simultaneously limiting production of carcinogenic toxins released by opportunistically pathogenic <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> (summarized in <xref ref-type="fig" rid="toxins-13-00346-f003">Figure 3</xref>b). Thus, a more nuanced understanding of how modulating the inflammatory environment alters colibactin concentrations may help direct treatment options in IBD patients with high levels of colibactin-producing bacteria, who may be at a higher risk for cancer progression.</p></sec><sec id="sec3dot3-toxins-13-00346"><title>3.3. Mucosal Adherence and Biofilm Formation</title><p>In vitro evidence that cell-to-cell contact is necessary for colibactin&#x02019;s genotoxic activity suggests that delivery of the molecule in vivo may necessitate <italic>pks</italic><sup>+</sup> bacteria somehow bypassing the protective mucosal barrier to interact directly with the host epithelium. <italic>E. coli</italic> possess various fimbral adhesins which promote binding and internalization at the colonic mucosa [<xref rid="B49-toxins-13-00346" ref-type="bibr">49</xref>], suggesting <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> may colonize and invade the mucosa increasing potential direct contact with epithelial cells. In tumor tissue, this is often the case: biopsies from CRC patients show a higher level of mucosally-invasive <italic>E. coli</italic> relative to normal adjacent tissue where <italic>E. coli</italic> aggregate at the mucosal surface (<xref ref-type="fig" rid="toxins-13-00346-f004">Figure 4</xref>) [<xref rid="B50-toxins-13-00346" ref-type="bibr">50</xref>,<xref rid="B51-toxins-13-00346" ref-type="bibr">51</xref>], and tumors with high microsatellite instability exhibit higher rates of mucosally-invasive <italic>E. coli</italic> [<xref rid="B26-toxins-13-00346" ref-type="bibr">26</xref>]. Clinical <italic>E. coli</italic> isolates exhibiting high mucosal invasion show high binding affinity to mucus secreting cells in vitro, with <italic>pks</italic><sup>+</sup> strains inducing high levels of DNA damage exacerbated by mucosal disruption [<xref rid="B52-toxins-13-00346" ref-type="bibr">52</xref>]. During inflammation, host production of nitric oxides and reactive oxygen species increases mucosal oxygenation, creating a microaerobic niche in which <italic>E. coli</italic> preferentially colonize (<xref ref-type="fig" rid="toxins-13-00346-f004">Figure 4</xref>) [<xref rid="B53-toxins-13-00346" ref-type="bibr">53</xref>,<xref rid="B54-toxins-13-00346" ref-type="bibr">54</xref>]. These changes may promote proliferation of mucosal <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> species during inflammation, providing a mechanism for colibactin induced oncogenesis in CAC.</p><p>At the mucosal interface, aggregating bacteria can encapsulate themselves in a self-secreted extracellular matrix (i.e., biofilm) to avoid perturbations from host defenses or the intestinal environment [<xref rid="B55-toxins-13-00346" ref-type="bibr">55</xref>]. Biofilm structures are often found in patients with intestinal disease, and promote intramucosal invasion [<xref rid="B56-toxins-13-00346" ref-type="bibr">56</xref>]. In <italic>E. coli</italic> strains producing genotoxins, biofilm association increases mucosal invasion depth which may facilitate the delivery of virulent small molecules to host epithelial cells (<xref ref-type="fig" rid="toxins-13-00346-f004">Figure 4</xref>). In two geographically distinct cohorts from the USA and Malaysia, right-sided (proximal) CRC cases almost universally (89%) harbored biofilms both at the tumor site and throughout the normal mucosa [<xref rid="B57-toxins-13-00346" ref-type="bibr">57</xref>]. While bacterial diversity in normal and tumor tissue did not differ, biofilm-covered CRCs exhibited higher bacterial invasion into the underlying tumor tissue [<xref rid="B57-toxins-13-00346" ref-type="bibr">57</xref>].</p><p>Several studies have used a combination of <italic>in-situ</italic> hybridization and 16S rRNA gene sequencing to investigate the composition of mucosal biofilms in CRC patients, frequently identifying Proteobacteria in mucosal biofilms from both tumor and normal adjacent tissue, with a high prevalence of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> (68%) in proximal CRC biofilms [<xref rid="B58-toxins-13-00346" ref-type="bibr">58</xref>,<xref rid="B59-toxins-13-00346" ref-type="bibr">59</xref>]. Biofilms harvested from both normal and tumor tissue from CRC increase mucosal invasion by gut microbes and induce a higher tumor burden in murine models [<xref rid="B60-toxins-13-00346" ref-type="bibr">60</xref>], suggesting some element of core biofilm structure, a commonly distributed biofilm-associated species, or a combination of these factors, promotes carcinogenesis. A causative role for <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> seems likely given their ubiquitous distribution throughout biofilms isolated from CRC patients. Co-infection with the biofilm initiating strain enterotoxigenic <italic>Bacteroides fragilis</italic> (ETBF) and <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> in specific pathogen free (SPF) mice demonstrate that biofilm association promotes mucosal invasion, expansion of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> populations, and a concomitant increase in &#x003b3;H2AX histological staining and tumor burden relative to monoassociation [<xref rid="B58-toxins-13-00346" ref-type="bibr">58</xref>]. ETBF may further promote interaction between <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> and host epithelial cells by degrading the protective mucus layer through an undetermined mechanism (see commentary [<xref rid="B61-toxins-13-00346" ref-type="bibr">61</xref>]), minimizing a crucial barrier for <italic>E. coli</italic> adherence. Importantly, deletion of <italic>B. fragilis</italic> toxin (ETBF) or colibactin (<italic>E. coli</italic>) diminished tumor burdens, suggesting the existence of a cooperative network between these toxins [<xref rid="B58-toxins-13-00346" ref-type="bibr">58</xref>]. However, the use of SPF mice in these experiments makes it difficult to distinguish if additional bacteria are involved in biofilm initiation and tumor development.</p><p>Altogether, these findings suggest that <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> association with microbial biofilms enhances colibactin&#x02019;s carcinogenic activity, possibly by increasing proximity to host epithelial cells and enhancing total abundance of these bacteria within the mucosa. In these scenarios, normally innocuous genotoxins secreted by the bacteria may occur in elevated doses near replicating host cells resulting in carcinogenic activity and CRC initiation or progression.</p></sec><sec id="sec3dot4-toxins-13-00346"><title>3.4. Modulation of Tumor Microenvironment</title><p>While colibactin can directly promote oncogenic transformation by DNA alkylation and subsequent mutagenesis in epithelial cells [<xref rid="B6-toxins-13-00346" ref-type="bibr">6</xref>,<xref rid="B9-toxins-13-00346" ref-type="bibr">9</xref>,<xref rid="B23-toxins-13-00346" ref-type="bibr">23</xref>,<xref rid="B29-toxins-13-00346" ref-type="bibr">29</xref>], its role in CRC progression extends beyond these activities by helping to establish a pro-carcinogenic environment supporting tumor growth [<xref rid="B62-toxins-13-00346" ref-type="bibr">62</xref>,<xref rid="B63-toxins-13-00346" ref-type="bibr">63</xref>,<xref rid="B64-toxins-13-00346" ref-type="bibr">64</xref>]. After <italic>pks</italic>-induced DNA damage, cells may undergo apoptosis, transformation, or senescence. Adoption of a senescent state induces a senescence-associated secretory phenotype (SASP) characterized by increased secretion of various growth factors that promote proliferation of nearby cells (<xref ref-type="fig" rid="toxins-13-00346-f002">Figure 2</xref>) [<xref rid="B62-toxins-13-00346" ref-type="bibr">62</xref>,<xref rid="B63-toxins-13-00346" ref-type="bibr">63</xref>]. These changes may occur near cells that have acquired <italic>pks</italic>-generated mutations in the <italic>APC</italic> or <italic>p53</italic> pathways after colibactin exposure [<xref rid="B29-toxins-13-00346" ref-type="bibr">29</xref>], further promoting unrestricted growth and tumor proliferation. A recent study demonstrated that the <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> strain 11G5 translocates to mesenteric lymph nodes in <italic>Apc</italic><sup>Min/+</sup> mice, with a concomitant reduction of some cytotoxic T cell lineages and an increase in regulatory T cells within infected lymph nodes [<xref rid="B64-toxins-13-00346" ref-type="bibr">64</xref>]. Furthermore, levels of cytotoxic T cells are reduced within the colonic mucosa of 11G5-colonized mice and invasive margins from tumor biopsies from CRC patients colonized by <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> [<xref rid="B64-toxins-13-00346" ref-type="bibr">64</xref>], suggesting that colibactin-producing microbes may create a pro-carcinogenic environment within the gut by modulating immune cell activity. Collectively, these observations suggest that colibactin-producing <italic>E. coli</italic> may create a &#x0201c;perfect storm&#x0201d; of tumorigenic potential, simultaneously promoting oncogenic transformation in epithelial cells and generating populations of bystander tumor-promoting cells while restricting immune activation. </p><p>Colibactin may also influence interactions between <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> and other intestinal bacteria, altering the complex ecological networks observed within gut microbiota communities [<xref rid="B65-toxins-13-00346" ref-type="bibr">65</xref>]. Shunt precolibactins have been shown to have mild inhibitory effects on the growth of a common probiotic, <italic>Bacillus subtilis</italic>, in vitro [<xref rid="B66-toxins-13-00346" ref-type="bibr">66</xref>]. The effects of colibactin on microbial communities in vivo remain poorly characterized, but at least one study has directly demonstrated that colonization by <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> in murine models reduces the relative abundance of Firmicutes and Clostridia [<xref rid="B67-toxins-13-00346" ref-type="bibr">67</xref>], taxa which represent a significant proportion of microbes in healthy individuals [<xref rid="B68-toxins-13-00346" ref-type="bibr">68</xref>]. Disruption of the ratio of Firmicutes to Bacteroidetes has been used as a marker of various metabolic disorders [<xref rid="B69-toxins-13-00346" ref-type="bibr">69</xref>] and a general measure of dysbiosis. The exact nature of how colibactin production may alter transcriptional regulation or abundance of gut microbes is not well understood. However, the relevance of microbial dysbiosis in the etiology of various cancers is well-defined [<xref rid="B70-toxins-13-00346" ref-type="bibr">70</xref>,<xref rid="B71-toxins-13-00346" ref-type="bibr">71</xref>,<xref rid="B72-toxins-13-00346" ref-type="bibr">72</xref>]. Future studies focusing on how colibactin influences multi-kingdom interactions in the gut may elucidate novel pathways by which <italic>pks</italic><sup>+</sup> bacterial colonization deleteriously affects their host.</p></sec></sec><sec sec-type="conclusions" id="sec4-toxins-13-00346"><title>4. Conclusions</title><p>Overrepresentation of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> in CRC cases has led to the hypothesis that these bacteria may directly promote tumorigenesis. Several biological characteristics of colibactin supports a role for this secondary molecule in carcinogenesis. First, colibactin contains two electrophilic cyclopropane warheads that bind adenine-rich motifs in host DNA, creating inter-strand cross-links that stall cell cycle progression and activate DNA damage response pathways. Infection with <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> causes somatic mutation that induces oncogenic transformation in colonoids and promotes tumor development in vivo. However, the prevalence of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> colonization far exceeds the observed proportion of individuals carrying mutational signatures attributed to the genotoxin, suggesting physiological context dictates the compounds genotoxic activity. This raises an important question: is the presence of <italic>pks</italic> genes enough to produce colibactin with functional genotoxic effect on host epithelium? An interesting case-study can be made by investigating the genotoxic potential of the commercially available probiotic strain <italic>E. coli</italic> Nissle 1917 (EcN), that has a long history of use as a beneficial probiotic [<xref rid="B73-toxins-13-00346" ref-type="bibr">73</xref>] despite carrying the <italic>pks</italic> biosynthetic gene cluster [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>]. Counterintuitively, the <italic>pks</italic> peptidase ClbP is actually essential for the antibacterial activity of EcN, contributing to the maturation of siderophores that enable this probiotic to outcompete pathogenic bacteria [<xref rid="B13-toxins-13-00346" ref-type="bibr">13</xref>]. Whether or not EcN infection results in DNA damage is debated. While one recent study reported no genotoxic effects of EcN were observable in cell lines or murine models [<xref rid="B74-toxins-13-00346" ref-type="bibr">74</xref>], others have demonstrated genotoxicity in mammalian cell lines attenuated by <italic>clbA</italic> mutation [<xref rid="B13-toxins-13-00346" ref-type="bibr">13</xref>]. Thus, more work is necessary to determine if these strains produce physiologically active colibactin, and if long-term intake of this probiotic may increase cancer risk.</p><p><italic>Pks</italic><sup>+</sup> bacteria may have relevance to cancer outside of the intestine. These bacteria frequently colonize extraintestinal sites and colibactin mutational signatures have been reported in a subset of patients with head and neck, urinary tract, neuroendocrine tumors, and ovarian cancer [<xref rid="B9-toxins-13-00346" ref-type="bibr">9</xref>]. A higher concentration of colibactin biosynthetic byproducts in the urine of patients with urinary tract infection (UTI) relative to healthy individuals, and an archetypal UTI strain of <italic>pks<sup>+</sup> E. coli</italic> causes DNA damage within the regenerative compartment of the bladder after transurethral infection in mice, suggesting a potential role for these microbes in bladder cancer [<xref rid="B75-toxins-13-00346" ref-type="bibr">75</xref>]. Two separate studies currently published as pre-prints have identified a high proportion of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> in association with DNA damage in biopsies from prostate cancer patients [<xref rid="B76-toxins-13-00346" ref-type="bibr">76</xref>] and <italic>pks</italic><sup>+</sup>&#x000a0;<italic>Klebsiella pneumoniae</italic> in a subset of hospital patients with liver abscess [<xref rid="B77-toxins-13-00346" ref-type="bibr">77</xref>]. These findings suggest that colibactin may play a role in a variety of cancers beyond CRC. Although solid evidence supports the case for colibactin as a carcinogen, the oncogenic potential of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> may be influenced by many factors altering colibactin production and localization within the intestinal tract. Colibactin&#x02019;s instability suggests it may only exhibit oncogenic activity while in close association with host epithelial cells, and limits mechanistic studies aimed at studying the effects of the toxin without influence from other aspects of bacterial infection or unrelated virulence factors. Because all colibactin-related studies utilize <italic>pks</italic> or <italic>clb</italic> mutants (e.g., [<xref rid="B3-toxins-13-00346" ref-type="bibr">3</xref>,<xref rid="B5-toxins-13-00346" ref-type="bibr">5</xref>,<xref rid="B6-toxins-13-00346" ref-type="bibr">6</xref>,<xref rid="B13-toxins-13-00346" ref-type="bibr">13</xref>]) which may influence other biosynthetic pathways in ways we do not completely understand [<xref rid="B78-toxins-13-00346" ref-type="bibr">78</xref>], it is difficult to attribute phenotypes directly to colibactin. Recent structural characterization of colibactin may facilitate the production of synthetic compounds which can be used to answer questions specifically regarding structure-activity relationship. These synthetic compounds would allow for more comprehensive and accurate screening methods capable of identifying pathways involved in DNA repair following exposure to <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic>, or for the derivation of targeted therapeutics which inhibit genotoxic activity by directly inhibiting colibactin&#x02019;s mechanism-of-action. Furthermore, it remains unclear how this large transitory molecule migrates from the bacterial periplasm to the host nucleus or which DNA repair pathways eukaryotic cells use to repair cross-links formed after colibactin exposure. Future studies should focus on clarifying fundamental aspects of colibactin&#x02019;s biology such as this, which remain mysterious and may inform future therapeutic approaches aimed at reducing <italic>pks</italic>-associated cancer risk. Pertinent research questions and potential clinical applications involving <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> are summarized in <xref ref-type="fig" rid="toxins-13-00346-f005">Figure 5</xref>.</p><p>The most evident question is related to colibactin&#x02019;s function within the microbiota. What biological advantage is gained by <italic>E. coli</italic> strains carrying the <italic>pks</italic> island? One would assume that the biosynthetic gene cluster confers a fitness advantage, but data supporting this function are limited. The extent of colibactin&#x02019;s activity on other microbes (bacteria, fungi, archaea, and viruses) inhabiting the intestine is unclear at best. It is intriguing to note that certain secondary metabolites generated from biosynthetic gene clusters are implicated in bacteria anti-phage defense response [<xref rid="B79-toxins-13-00346" ref-type="bibr">79</xref>], thereby favoring fitness to bacteria carrying this weaponry. Whether the secondary metabolite colibactin enhances bacterial fitness through anti-phage responses is currently unknown. On the flip side, colibactin analogs may find applications as chemotherapeutic agents. For example, the NPRS/PKS molecule bleomycin, which induces DNA damage is currently used as anti-cancer drug for various form of cancers [<xref rid="B80-toxins-13-00346" ref-type="bibr">80</xref>]. There is a long road ahead before colibactin finds application in chemotherapy and for now, all efforts are focused on its cancer promoting ability.</p><p>Evidence suggests that <italic>pks</italic>-derived mutational signatures are acquired during childhood [<xref rid="B9-toxins-13-00346" ref-type="bibr">9</xref>,<xref rid="B31-toxins-13-00346" ref-type="bibr">31</xref>] and thus may contribute towards oncogenic transformation which does not appear for decades, until additional factors promote tumorigenesis. The ubiquity of B2 phylogroup <italic>E. coli</italic> in the human microbiome, especially at early age [<xref rid="B81-toxins-13-00346" ref-type="bibr">81</xref>], raise the concern of long-term consequences on DNA integrity in asymptomatic hosts. However, until further clinical evidence assigns a clear carcinogenic label to <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic>, the need for childhood screening is nonexistent. If this moment ever arises, the challenge would be to design precision microbiome interventions since antibiotic approach would likely do more harm than good in this young population. Engineered probiotics [<xref rid="B82-toxins-13-00346" ref-type="bibr">82</xref>] may be designed to specifically target <italic>pks</italic><sup>+</sup> microbes or produce metabolites which directly interrupt colibactin activity. Such small molecule inhibitors may come from a self-resistance component of the <italic>pks</italic> island itself, the cyclopropane hydrolase ClbS, which disrupts active cyclopropane sites in colibactin [<xref rid="B83-toxins-13-00346" ref-type="bibr">83</xref>,<xref rid="B84-toxins-13-00346" ref-type="bibr">84</xref>]. Phage screening may identify viruses capable of targeted depletion of specific microbial species [<xref rid="B85-toxins-13-00346" ref-type="bibr">85</xref>], and screening <italic>pks</italic><sup>+</sup> isolates from individuals against phage libraries may allow for the creation of personalized phage cocktails with high activity for patient-specific strains. Such an approach has been used in pre-clinical model of CRC driven by <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> [<xref rid="B86-toxins-13-00346" ref-type="bibr">86</xref>]. In addition, predatory bacteria against AIEC such as <italic>Bdellovibrio bacteriovorus</italic> could represent another means to selectively deplete <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E.coli</italic> from a complex community [<xref rid="B87-toxins-13-00346" ref-type="bibr">87</xref>]. In conclusion, it has been a remarkable journey from <italic>pks</italic>/colibactin&#x02019;s discovery to molecular structure characterization and potential in vivo function. Yet, much remains to be addressed regarding this fascinating molecule and the years to come promise to be exciting for this field of research. </p></sec></body><back><ack><title>Acknowledgments</title><p>The authors gratefully acknowledge Kevin M. Wernke for critical revision of sections related to colibactin structure and diagrammatic representations of the molecule. Figures were made using BioRender.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.W.D., writing&#x02014;original draft preparation; C.J., writing&#x02014;review and editing; supervision; funding acquisition. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by National Institutes of Health, grant number R01CA215553-O1A1, University of Florida Health Cancer Center Funds and University of Florida Department of Medicine Gatorade Funds.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-toxins-13-00346"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenaillon</surname><given-names>O.</given-names></name><name><surname>Skurnik</surname><given-names>D.</given-names></name><name><surname>Picard</surname><given-names>B.</given-names></name><name><surname>Denamur</surname><given-names>E.</given-names></name></person-group><article-title>The population genetics of commensal <italic>Escherichia coli</italic></article-title><source>Nat. Rev. Microbiol.</source><year>2010</year><volume>8</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2298</pub-id><pub-id pub-id-type="pmid">20157339</pub-id></element-citation></ref><ref id="B2-toxins-13-00346"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messerer</surname><given-names>M.</given-names></name><name><surname>Fischer</surname><given-names>W.</given-names></name><name><surname>Schubert</surname><given-names>S.</given-names></name></person-group><article-title>Investigation of horizontal gene transfer of pathogenicity islands in <italic>Escherichia coli</italic> using next-generation sequencing</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0179880</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0179880</pub-id><pub-id pub-id-type="pmid">28732043</pub-id></element-citation></ref><ref id="B3-toxins-13-00346"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name><name><surname>Homburg</surname><given-names>S.</given-names></name><name><surname>Taieb</surname><given-names>F.</given-names></name><name><surname>Boury</surname><given-names>M.</given-names></name><name><surname>Brzuszkiewicz</surname><given-names>E.</given-names></name><name><surname>Gottschalk</surname><given-names>G.</given-names></name><name><surname>Buchrieser</surname><given-names>C.</given-names></name><name><surname>Hacker</surname><given-names>J.</given-names></name><name><surname>Dobrindt</surname><given-names>U.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name></person-group><article-title><italic>Escherichia coli</italic> induces DNA double-strand breaks in eukaryotic cells</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>848</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1126/science.1127059</pub-id><pub-id pub-id-type="pmid">16902142</pub-id></element-citation></ref><ref id="B4-toxins-13-00346"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>J.C.</given-names></name><name><surname>Perez-Chanona</surname><given-names>E.</given-names></name><name><surname>M&#x000fc;hlbauer</surname><given-names>M.</given-names></name><name><surname>Tomkovich</surname><given-names>S.</given-names></name><name><surname>Uronis</surname><given-names>J.M.</given-names></name><name><surname>Fan</surname><given-names>T.-J.</given-names></name><name><surname>Campbell</surname><given-names>B.J.</given-names></name><name><surname>Abujamel</surname><given-names>T.</given-names></name><name><surname>Dogan</surname><given-names>B.</given-names></name><name><surname>Rogers</surname><given-names>A.B.</given-names></name><etal/></person-group><article-title>Intestinal inflammation targets cancer-inducing activity of the microbiota</article-title><source>Science</source><year>2012</year><volume>338</volume><fpage>120</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1126/science.1224820</pub-id><?supplied-pmid 22903521?><pub-id pub-id-type="pmid">22903521</pub-id></element-citation></ref><ref id="B5-toxins-13-00346"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>C.S.</given-names></name><name><surname>Healy</surname><given-names>A.R.</given-names></name><name><surname>Wernke</surname><given-names>K.M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Frischling</surname><given-names>M.C.</given-names></name><name><surname>Shine</surname><given-names>E.E.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Herzon</surname><given-names>S.B.</given-names></name><name><surname>Crawford</surname><given-names>J.M.</given-names></name></person-group><article-title>Structure elucidation of colibactin and its DNA cross-links</article-title><source>Science</source><year>2019</year><volume>365</volume><fpage>eaax2685</fpage><pub-id pub-id-type="doi">10.1126/science.aax2685</pub-id><?supplied-pmid 31395743?><pub-id pub-id-type="pmid">31395743</pub-id></element-citation></ref><ref id="B6-toxins-13-00346"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossuet-Greif</surname><given-names>N.</given-names></name><name><surname>Vignard</surname><given-names>J.</given-names></name><name><surname>Taieb</surname><given-names>F.</given-names></name><name><surname>Mirey</surname><given-names>G.</given-names></name><name><surname>Dubois</surname><given-names>D.</given-names></name><name><surname>Petit</surname><given-names>C.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name></person-group><article-title>The Colibactin Genotoxin Generates DNA Interstrand Cross-Links in Infected Cells</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e02393-17</fpage><pub-id pub-id-type="doi">10.1128/mBio.02393-17</pub-id><?supplied-pmid 29559578?><pub-id pub-id-type="pmid">29559578</pub-id></element-citation></ref><ref id="B7-toxins-13-00346"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizcaino</surname><given-names>M.I.</given-names></name><name><surname>Crawford</surname><given-names>J.M.</given-names></name></person-group><article-title>The colibactin warhead crosslinks DNA</article-title><source>Nat. Chem.</source><year>2015</year><volume>7</volume><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1038/nchem.2221</pub-id><?supplied-pmid 25901819?><pub-id pub-id-type="pmid">25901819</pub-id></element-citation></ref><ref id="B8-toxins-13-00346"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>L.B.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Haradhvala</surname><given-names>N.J.</given-names></name><name><surname>Huang</surname><given-names>M.N.</given-names></name><name><surname>Tian Ng</surname><given-names>A.W.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Boot</surname><given-names>A.</given-names></name><name><surname>Covington</surname><given-names>K.R.</given-names></name><name><surname>Gordenin</surname><given-names>D.A.</given-names></name><name><surname>Bergstrom</surname><given-names>E.N.</given-names></name><etal/></person-group><article-title>The repertoire of mutational signatures in human cancer</article-title><source>Nature</source><year>2020</year><volume>578</volume><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1943-3</pub-id><?supplied-pmid 32025018?><pub-id pub-id-type="pmid">32025018</pub-id></element-citation></ref><ref id="B9-toxins-13-00346"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleguezuelos-Manzano</surname><given-names>C.</given-names></name><name><surname>Puschhof</surname><given-names>J.</given-names></name><name><surname>Rosendahl Huber</surname><given-names>A.</given-names></name><name><surname>van Hoeck</surname><given-names>A.</given-names></name><name><surname>Wood</surname><given-names>H.M.</given-names></name><name><surname>Nomburg</surname><given-names>J.</given-names></name><name><surname>Gurjao</surname><given-names>C.</given-names></name><name><surname>Manders</surname><given-names>F.</given-names></name><name><surname>Dalmasso</surname><given-names>G.</given-names></name><name><surname>Stege</surname><given-names>P.B.</given-names></name><etal/></person-group><article-title>Mutational signature in colorectal cancer caused by genotoxic <italic>pks</italic><sup>+</sup>
<italic>E. coli</italic></article-title><source>Nature</source><year>2020</year><volume>580</volume><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2080-8</pub-id><pub-id pub-id-type="pmid">32106218</pub-id></element-citation></ref><ref id="B10-toxins-13-00346"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wassenaar</surname><given-names>T.M.</given-names></name></person-group><article-title><italic>E. coli</italic> and colorectal cancer: A complex relationship that deserves a critical mindset</article-title><source>Crit. Rev. Microbiol.</source><year>2018</year><volume>44</volume><fpage>619</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1080/1040841X.2018.1481013</pub-id><pub-id pub-id-type="pmid">29909724</pub-id></element-citation></ref><ref id="B11-toxins-13-00346"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallenstein</surname><given-names>A.</given-names></name><name><surname>Rehm</surname><given-names>N.</given-names></name><name><surname>Brinkmann</surname><given-names>M.</given-names></name><name><surname>Selle</surname><given-names>M.</given-names></name><name><surname>Bossuet-Greif</surname><given-names>N.</given-names></name><name><surname>Sauer</surname><given-names>D.</given-names></name><name><surname>Bunk</surname><given-names>B.</given-names></name><name><surname>Spr&#x000f6;er</surname><given-names>C.</given-names></name><name><surname>Wami</surname><given-names>H.T.</given-names></name><name><surname>Homburg</surname><given-names>S.</given-names></name><etal/></person-group><article-title>ClbR Is the Key Transcriptional Activator of Colibactin Gene Expression in <italic>Escherichia coli</italic></article-title><source>mSphere</source><year>2020</year><volume>5</volume><fpage>e00591-20</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00591-20</pub-id><pub-id pub-id-type="pmid">32669458</pub-id></element-citation></ref><ref id="B12-toxins-13-00346"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tronnet</surname><given-names>S.</given-names></name><name><surname>Garcie</surname><given-names>C.</given-names></name><name><surname>Brachmann</surname><given-names>A.O.</given-names></name><name><surname>Piel</surname><given-names>J.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name></person-group><article-title>High iron supply inhibits the synthesis of the genotoxin colibactin by pathogenic <italic>Escherichia coli</italic> through a non-canonical Fur/RyhB-mediated pathway</article-title><source>Pathog. Dis.</source><year>2017</year><volume>75</volume><fpage>ftx066</fpage><pub-id pub-id-type="doi">10.1093/femspd/ftx066</pub-id></element-citation></ref><ref id="B13-toxins-13-00346"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massip</surname><given-names>C.</given-names></name><name><surname>Branchu</surname><given-names>P.</given-names></name><name><surname>Bossuet-Greif</surname><given-names>N.</given-names></name><name><surname>Chagneau</surname><given-names>C.V.</given-names></name><name><surname>Gaillard</surname><given-names>D.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name><name><surname>Boury</surname><given-names>M.</given-names></name><name><surname>S&#x000e9;cher</surname><given-names>T.</given-names></name><name><surname>Dubois</surname><given-names>D.</given-names></name><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name><etal/></person-group><article-title>Deciphering the interplay between the genotoxic and probiotic activities of <italic>Escherichia coli</italic> Nissle 1917</article-title><source>PLoS Pathog.</source><year>2019</year><volume>15</volume><elocation-id>e1008029</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008029</pub-id><pub-id pub-id-type="pmid">31545853</pub-id></element-citation></ref><ref id="B14-toxins-13-00346"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chagneau</surname><given-names>C.V.</given-names></name><name><surname>Garcie</surname><given-names>C.</given-names></name><name><surname>Bossuet-Greif</surname><given-names>N.</given-names></name><name><surname>Tronnet</surname><given-names>S.</given-names></name><name><surname>Brachmann</surname><given-names>A.O.</given-names></name><name><surname>Piel</surname><given-names>J.</given-names></name><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name></person-group><article-title>The polyamine spermidine modulates the production of the bacterial genotoxin colibactin</article-title><source>mSphere</source><year>2019</year><volume>4</volume><fpage>e00414-19</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00414-19</pub-id><pub-id pub-id-type="pmid">31578245</pub-id></element-citation></ref><ref id="B15-toxins-13-00346"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tronnet</surname><given-names>S.</given-names></name><name><surname>Garcie</surname><given-names>C.</given-names></name><name><surname>Rehm</surname><given-names>N.</given-names></name><name><surname>Dobrindt</surname><given-names>U.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name></person-group><article-title>Iron Homeostasis Regulates the Genotoxicity of <italic>Escherichia coli</italic> That Produces Colibactin</article-title><source>Infect. Immun.</source><year>2016</year><volume>84</volume><fpage>3358</fpage><lpage>3368</lpage><pub-id pub-id-type="doi">10.1128/IAI.00659-16</pub-id><?supplied-pmid 27620723?><pub-id pub-id-type="pmid">27620723</pub-id></element-citation></ref><ref id="B16-toxins-13-00346"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>P.</given-names></name><name><surname>Marcq</surname><given-names>I.</given-names></name><name><surname>Magistro</surname><given-names>G.</given-names></name><name><surname>Penary</surname><given-names>M.</given-names></name><name><surname>Garcie</surname><given-names>C.</given-names></name><name><surname>Payros</surname><given-names>D.</given-names></name><name><surname>Boury</surname><given-names>M.</given-names></name><name><surname>Olier</surname><given-names>M.</given-names></name><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name><name><surname>Audebert</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Interplay between siderophores and colibactin genotoxin biosynthetic pathways in <italic>Escherichia coli</italic></article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003437</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003437</pub-id><pub-id pub-id-type="pmid">23853582</pub-id></element-citation></ref><ref id="B17-toxins-13-00346"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkova</surname><given-names>N.V.</given-names></name><name><surname>Meier</surname><given-names>B.</given-names></name><name><surname>Gonz&#x000e1;lez-Huici</surname><given-names>V.</given-names></name><name><surname>Bertolini</surname><given-names>S.</given-names></name><name><surname>Gonzalez</surname><given-names>S.</given-names></name><name><surname>V&#x000f6;hringer</surname><given-names>H.</given-names></name><name><surname>Abascal</surname><given-names>F.</given-names></name><name><surname>Martincorena</surname><given-names>I.</given-names></name><name><surname>Campbell</surname><given-names>P.J.</given-names></name><name><surname>Gartner</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mutational signatures are jointly shaped by DNA damage and repair</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2169</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15912-7</pub-id><pub-id pub-id-type="pmid">32358516</pub-id></element-citation></ref><ref id="B18-toxins-13-00346"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeijmakers</surname><given-names>J.H.J.</given-names></name></person-group><article-title>DNA damage, aging, and cancer</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>1475</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0804615</pub-id><?supplied-pmid 19812404?><pub-id pub-id-type="pmid">19812404</pub-id></element-citation></ref><ref id="B19-toxins-13-00346"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousa</surname><given-names>J.J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Tomkovich</surname><given-names>S.</given-names></name><name><surname>Shima</surname><given-names>A.</given-names></name><name><surname>Newsome</surname><given-names>R.C.</given-names></name><name><surname>Tripathi</surname><given-names>P.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name><name><surname>Bruner</surname><given-names>S.D.</given-names></name><name><surname>Jobin</surname><given-names>C.</given-names></name></person-group><article-title>MATE transport of the E. coli-derived genotoxin colibactin</article-title><source>Nat. Microbiol.</source><year>2016</year><volume>1</volume><fpage>15009</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2015.9</pub-id><?supplied-pmid 27571755?><pub-id pub-id-type="pmid">27571755</pub-id></element-citation></ref><ref id="B20-toxins-13-00346"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brotherton</surname><given-names>C.A.</given-names></name><name><surname>Balskus</surname><given-names>E.P.</given-names></name></person-group><article-title>A prodrug resistance mechanism is involved in colibactin biosynthesis and cytotoxicity</article-title><source>J. Am. Chem. Soc.</source><year>2013</year><volume>135</volume><fpage>3359</fpage><lpage>3362</lpage><pub-id pub-id-type="doi">10.1021/ja312154m</pub-id><pub-id pub-id-type="pmid">23406518</pub-id></element-citation></ref><ref id="B21-toxins-13-00346"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wernke</surname><given-names>K.M.</given-names></name><name><surname>Xue</surname><given-names>M.</given-names></name><name><surname>Tirla</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>C.S.</given-names></name><name><surname>Crawford</surname><given-names>J.M.</given-names></name><name><surname>Herzon</surname><given-names>S.B.</given-names></name></person-group><article-title>Structure and bioactivity of colibactin</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2020</year><volume>30</volume><fpage>127280</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127280</pub-id><?supplied-pmid 32527463?><pub-id pub-id-type="pmid">32527463</pub-id></element-citation></ref><ref id="B22-toxins-13-00346"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>M.R.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Villalta</surname><given-names>P.W.</given-names></name><name><surname>Stornetta</surname><given-names>A.</given-names></name><name><surname>Boudreau</surname><given-names>P.D.</given-names></name><name><surname>Carr&#x000e1;</surname><given-names>A.</given-names></name><name><surname>Brennan</surname><given-names>C.A.</given-names></name><name><surname>Chun</surname><given-names>E.</given-names></name><name><surname>Ngo</surname><given-names>L.</given-names></name><name><surname>Samson</surname><given-names>L.D.</given-names></name><etal/></person-group><article-title>The human gut bacterial genotoxin colibactin alkylates DNA</article-title><source>Science</source><year>2019</year><volume>363</volume><fpage>eaar7785</fpage><pub-id pub-id-type="doi">10.1126/science.aar7785</pub-id><?supplied-pmid 30765538?><pub-id pub-id-type="pmid">30765538</pub-id></element-citation></ref><ref id="B23-toxins-13-00346"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dziuba&#x00144;ska-Kusibab</surname><given-names>P.J.</given-names></name><name><surname>Berger</surname><given-names>H.</given-names></name><name><surname>Battistini</surname><given-names>F.</given-names></name><name><surname>Bouwman</surname><given-names>B.A.M.</given-names></name><name><surname>Iftekhar</surname><given-names>A.</given-names></name><name><surname>Katainen</surname><given-names>R.</given-names></name><name><surname>Cajuso</surname><given-names>T.</given-names></name><name><surname>Crosetto</surname><given-names>N.</given-names></name><name><surname>Orozco</surname><given-names>M.</given-names></name><name><surname>Aaltonen</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Colibactin DNA-damage signature indicates mutational impact in colorectal cancer</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1063</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0908-2</pub-id><pub-id pub-id-type="pmid">32483361</pub-id></element-citation></ref><ref id="B24-toxins-13-00346"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuevas-Ramos</surname><given-names>G.</given-names></name><name><surname>Petit</surname><given-names>C.R.</given-names></name><name><surname>Marcq</surname><given-names>I.</given-names></name><name><surname>Boury</surname><given-names>M.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name></person-group><article-title><italic>Escherichia coli</italic> induces DNA damage in vivo and triggers genomic instability in mammalian cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>11537</fpage><lpage>11542</lpage><pub-id pub-id-type="doi">10.1073/pnas.1001261107</pub-id><?supplied-pmid 20534522?><pub-id pub-id-type="pmid">20534522</pub-id></element-citation></ref><ref id="B25-toxins-13-00346"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>N.</given-names></name><name><surname>Takahashi</surname><given-names>A.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Ohnishi</surname><given-names>T.</given-names></name></person-group><article-title>DNA damage induced by alkylating agents and repair pathways</article-title><source>J. Nucleic Acids</source><year>2010</year><volume>2010</volume><fpage>543531</fpage><pub-id pub-id-type="doi">10.4061/2010/543531</pub-id><pub-id pub-id-type="pmid">21113301</pub-id></element-citation></ref><ref id="B26-toxins-13-00346"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddocks</surname><given-names>O.D.K.</given-names></name><name><surname>Scanlon</surname><given-names>K.M.</given-names></name><name><surname>Donnenberg</surname><given-names>M.S.</given-names></name></person-group><article-title>An <italic>Escherichia coli</italic> effector protein promotes host mutation via depletion of DNA mismatch repair proteins</article-title><source>mBio</source><year>2013</year><volume>4</volume><fpage>e00152-13</fpage><pub-id pub-id-type="doi">10.1128/mBio.00152-13</pub-id><pub-id pub-id-type="pmid">23781066</pub-id></element-citation></ref><ref id="B27-toxins-13-00346"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>C.</given-names></name><name><surname>Salesse</surname><given-names>L.</given-names></name><name><surname>Hoang</surname><given-names>M.H.T.</given-names></name><name><surname>Bonnet</surname><given-names>M.</given-names></name><name><surname>Sauvanet</surname><given-names>P.</given-names></name><name><surname>Larabi</surname><given-names>A.</given-names></name><name><surname>Godfraind</surname><given-names>C.</given-names></name><name><surname>Gagni&#x000e8;re</surname><given-names>J.</given-names></name><name><surname>Pezet</surname><given-names>D.</given-names></name><name><surname>Rosenstiel</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Autophagy of Intestinal Epithelial Cells Inhibits Colorectal Carcinogenesis Induced by Colibactin-Producing <italic>Escherichia coli</italic> in ApcMin/+ Mice</article-title><source>Gastroenterology</source><year>2020</year><volume>158</volume><fpage>1373</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.12.026</pub-id><pub-id pub-id-type="pmid">31917256</pub-id></element-citation></ref><ref id="B28-toxins-13-00346"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murase</surname><given-names>K.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name><name><surname>Porcheron</surname><given-names>G.</given-names></name><name><surname>Houle</surname><given-names>S.</given-names></name><name><surname>Helloin</surname><given-names>E.</given-names></name><name><surname>P&#x000e9;nary</surname><given-names>M.</given-names></name><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name><name><surname>Dozois</surname><given-names>C.M.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name></person-group><article-title>HlyF Produced by Extraintestinal Pathogenic <italic>Escherichia coli</italic> Is a Virulence Factor That Regulates Outer Membrane Vesicle Biogenesis</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>213</volume><fpage>856</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv506</pub-id><pub-id pub-id-type="pmid">26494774</pub-id></element-citation></ref><ref id="B29-toxins-13-00346"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iftekhar</surname><given-names>A.</given-names></name><name><surname>Berger</surname><given-names>H.</given-names></name><name><surname>Bouznad</surname><given-names>N.</given-names></name><name><surname>Heuberger</surname><given-names>J.</given-names></name><name><surname>Boccellato</surname><given-names>F.</given-names></name><name><surname>Dobrindt</surname><given-names>U.</given-names></name><name><surname>Hermeking</surname><given-names>H.</given-names></name><name><surname>Sigal</surname><given-names>M.</given-names></name><name><surname>Meyer</surname><given-names>T.F.</given-names></name></person-group><article-title>Genomic aberrations after short-term exposure to colibactin-producing E. coli transform primary colon epithelial cells</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1003</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21162-y</pub-id><pub-id pub-id-type="pmid">33579932</pub-id></element-citation></ref><ref id="B30-toxins-13-00346"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Jobin</surname><given-names>C.</given-names></name></person-group><article-title>A mutational signature that can be made by a bacterium arises in human colon cancer</article-title><source>Nature</source><year>2020</year><volume>580</volume><fpage>194</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-00818-7</pub-id><pub-id pub-id-type="pmid">32203380</pub-id></element-citation></ref><ref id="B31-toxins-13-00346"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee-Six</surname><given-names>H.</given-names></name><name><surname>Olafsson</surname><given-names>S.</given-names></name><name><surname>Ellis</surname><given-names>P.</given-names></name><name><surname>Osborne</surname><given-names>R.J.</given-names></name><name><surname>Sanders</surname><given-names>M.A.</given-names></name><name><surname>Moore</surname><given-names>L.</given-names></name><name><surname>Georgakopoulos</surname><given-names>N.</given-names></name><name><surname>Torrente</surname><given-names>F.</given-names></name><name><surname>Noorani</surname><given-names>A.</given-names></name><name><surname>Goddard</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The landscape of somatic mutation in normal colorectal epithelial cells</article-title><source>Nature</source><year>2019</year><volume>574</volume><fpage>532</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1672-7</pub-id><pub-id pub-id-type="pmid">31645730</pub-id></element-citation></ref><ref id="B32-toxins-13-00346"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnbough</surname><given-names>C.L.</given-names></name></person-group><article-title>Regulation of bacterial gene expression by transcription attenuation</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2019</year><volume>83</volume><fpage>e00019-19</fpage><pub-id pub-id-type="doi">10.1128/MMBR.00019-19</pub-id><pub-id pub-id-type="pmid">31270135</pub-id></element-citation></ref><ref id="B33-toxins-13-00346"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raibaud</surname><given-names>O.</given-names></name><name><surname>Schwartz</surname><given-names>M.</given-names></name></person-group><article-title>Positive control of transcription initiation in bacteria</article-title><source>Annu. Rev. Genet.</source><year>1984</year><volume>18</volume><fpage>173</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1146/annurev.ge.18.120184.001133</pub-id><pub-id pub-id-type="pmid">6084980</pub-id></element-citation></ref><ref id="B34-toxins-13-00346"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trastoy</surname><given-names>R.</given-names></name><name><surname>Manso</surname><given-names>T.</given-names></name><name><surname>Fern&#x000e1;ndez-Garc&#x000ed;a</surname><given-names>L.</given-names></name><name><surname>Blasco</surname><given-names>L.</given-names></name><name><surname>Ambroa</surname><given-names>A.</given-names></name><name><surname>P&#x000e9;rez Del Molino</surname><given-names>M.L.</given-names></name><name><surname>Bou</surname><given-names>G.</given-names></name><name><surname>Garc&#x000ed;a-Contreras</surname><given-names>R.</given-names></name><name><surname>Wood</surname><given-names>T.K.</given-names></name><name><surname>Tom&#x000e1;s</surname><given-names>M.</given-names></name></person-group><article-title>Mechanisms of bacterial tolerance and persistence in the gastrointestinal and respiratory environments</article-title><source>Clin. Microbiol. Rev.</source><year>2018</year><volume>31</volume><fpage>e00023-18</fpage><pub-id pub-id-type="doi">10.1128/CMR.00023-18</pub-id><?supplied-pmid 30068737?><pub-id pub-id-type="pmid">30068737</pub-id></element-citation></ref><ref id="B35-toxins-13-00346"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homburg</surname><given-names>S.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name><name><surname>Hacker</surname><given-names>J.</given-names></name><name><surname>Dobrindt</surname><given-names>U.</given-names></name></person-group><article-title>Expression analysis of the colibactin gene cluster coding for a novel polyketide in <italic>Escherichia coli</italic></article-title><source>FEMS Microbiol. Lett.</source><year>2007</year><volume>275</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2007.00889.x</pub-id><pub-id pub-id-type="pmid">17714479</pub-id></element-citation></ref><ref id="B36-toxins-13-00346"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Limenitakis</surname><given-names>J.P.</given-names></name><name><surname>Fuhrer</surname><given-names>T.</given-names></name><name><surname>Geuking</surname><given-names>M.B.</given-names></name><name><surname>Lawson</surname><given-names>M.A.</given-names></name><name><surname>Wyss</surname><given-names>M.</given-names></name><name><surname>Brugiroux</surname><given-names>S.</given-names></name><name><surname>Keller</surname><given-names>I.</given-names></name><name><surname>Macpherson</surname><given-names>J.A.</given-names></name><name><surname>Rupp</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The outer mucus layer hosts a distinct intestinal microbial niche</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>8292</fpage><pub-id pub-id-type="doi">10.1038/ncomms9292</pub-id><pub-id pub-id-type="pmid">26392213</pub-id></element-citation></ref><ref id="B37-toxins-13-00346"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliero</surname><given-names>M.</given-names></name><name><surname>Calv&#x000e9;</surname><given-names>A.</given-names></name><name><surname>Fragoso</surname><given-names>G.</given-names></name><name><surname>Cuisiniere</surname><given-names>T.</given-names></name><name><surname>Hajjar</surname><given-names>R.</given-names></name><name><surname>Dobrindt</surname><given-names>U.</given-names></name><name><surname>Santos</surname><given-names>M.M.</given-names></name></person-group><article-title>Oligosaccharides increase the genotoxic effect of colibactin produced by pks+ <italic>Escherichia coli</italic> strains</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><elocation-id>172</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-021-07876-8</pub-id><pub-id pub-id-type="pmid">33596864</pub-id></element-citation></ref><ref id="B38-toxins-13-00346"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaitha</surname><given-names>S.</given-names></name><name><surname>Bashir</surname><given-names>M.</given-names></name><name><surname>Ali</surname><given-names>T.</given-names></name></person-group><article-title>Iron deficiency anemia in inflammatory bowel disease</article-title><source>World J. Gastrointest. Pathophysiol.</source><year>2015</year><volume>6</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.4291/wjgp.v6.i3.62</pub-id><?supplied-pmid 26301120?><pub-id pub-id-type="pmid">26301120</pub-id></element-citation></ref><ref id="B39-toxins-13-00346"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mark-Christensen</surname><given-names>A.</given-names></name><name><surname>Laurberg</surname><given-names>S.</given-names></name><name><surname>Haboubi</surname><given-names>N.</given-names></name></person-group><article-title>Dysplasia in inflammatory bowel disease: Historical review, critical histopathological analysis, and clinical implications</article-title><source>Inflamm. Bowel Dis.</source><year>2018</year><volume>24</volume><fpage>1895</fpage><lpage>1903</lpage><pub-id pub-id-type="doi">10.1093/ibd/izy075</pub-id><pub-id pub-id-type="pmid">29668897</pub-id></element-citation></ref><ref id="B40-toxins-13-00346"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terzi&#x00107;</surname><given-names>J.</given-names></name><name><surname>Grivennikov</surname><given-names>S.</given-names></name><name><surname>Karin</surname><given-names>E.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>Inflammation and colon cancer</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>2101</fpage><lpage>2114.e5</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.01.058</pub-id><?supplied-pmid 20420949?><pub-id pub-id-type="pmid">20420949</pub-id></element-citation></ref><ref id="B41-toxins-13-00346"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupp</surname><given-names>C.</given-names></name><name><surname>Robertson</surname><given-names>M.L.</given-names></name><name><surname>Wickham</surname><given-names>M.E.</given-names></name><name><surname>Sekirov</surname><given-names>I.</given-names></name><name><surname>Champion</surname><given-names>O.L.</given-names></name><name><surname>Gaynor</surname><given-names>E.C.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae</article-title><source>Cell Host Microbe</source><year>2007</year><volume>2</volume><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2007.06.010</pub-id><pub-id pub-id-type="pmid">18005726</pub-id></element-citation></ref><ref id="B42-toxins-13-00346"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raisch</surname><given-names>J.</given-names></name><name><surname>Buc</surname><given-names>E.</given-names></name><name><surname>Bonnet</surname><given-names>M.</given-names></name><name><surname>Sauvanet</surname><given-names>P.</given-names></name><name><surname>Vazeille</surname><given-names>E.</given-names></name><name><surname>de Vall&#x000e9;e</surname><given-names>A.</given-names></name><name><surname>D&#x000e9;chelotte</surname><given-names>P.</given-names></name><name><surname>Darcha</surname><given-names>C.</given-names></name><name><surname>Pezet</surname><given-names>D.</given-names></name><name><surname>Bonnet</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Colon cancer-associated B2 <italic>Escherichia coli</italic> colonize gut mucosa and promote cell proliferation</article-title><source>World J. Gastroenterol.</source><year>2014</year><volume>20</volume><fpage>6560</fpage><lpage>6572</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i21.6560</pub-id><pub-id pub-id-type="pmid">24914378</pub-id></element-citation></ref><ref id="B43-toxins-13-00346"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buc</surname><given-names>E.</given-names></name><name><surname>Dubois</surname><given-names>D.</given-names></name><name><surname>Sauvanet</surname><given-names>P.</given-names></name><name><surname>Raisch</surname><given-names>J.</given-names></name><name><surname>Delmas</surname><given-names>J.</given-names></name><name><surname>Darfeuille-Michaud</surname><given-names>A.</given-names></name><name><surname>Pezet</surname><given-names>D.</given-names></name><name><surname>Bonnet</surname><given-names>R.</given-names></name></person-group><article-title>High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e56964</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0056964</pub-id><?supplied-pmid 23457644?><pub-id pub-id-type="pmid">23457644</pub-id></element-citation></ref><ref id="B44-toxins-13-00346"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>J.C.</given-names></name><name><surname>Gharaibeh</surname><given-names>R.Z.</given-names></name><name><surname>M&#x000fc;hlbauer</surname><given-names>M.</given-names></name><name><surname>Perez-Chanona</surname><given-names>E.</given-names></name><name><surname>Uronis</surname><given-names>J.M.</given-names></name><name><surname>McCafferty</surname><given-names>J.</given-names></name><name><surname>Fodor</surname><given-names>A.A.</given-names></name><name><surname>Jobin</surname><given-names>C.</given-names></name></person-group><article-title>Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>4724</fpage><pub-id pub-id-type="doi">10.1038/ncomms5724</pub-id><?supplied-pmid 25182170?><pub-id pub-id-type="pmid">25182170</pub-id></element-citation></ref><ref id="B45-toxins-13-00346"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Miyata</surname><given-names>N.</given-names></name><name><surname>Winter</surname><given-names>M.G.</given-names></name><name><surname>Arenales</surname><given-names>A.</given-names></name><name><surname>Hughes</surname><given-names>E.R.</given-names></name><name><surname>Spiga</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Sifuentes-Dominguez</surname><given-names>L.</given-names></name><name><surname>Starokadomskyy</surname><given-names>P.</given-names></name><name><surname>Gopal</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer</article-title><source>J. Exp. Med.</source><year>2019</year><volume>216</volume><fpage>2378</fpage><lpage>2393</lpage><pub-id pub-id-type="doi">10.1084/jem.20181939</pub-id><pub-id pub-id-type="pmid">31358565</pub-id></element-citation></ref><ref id="B46-toxins-13-00346"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Gharaibeh</surname><given-names>R.Z.</given-names></name><name><surname>Newsome</surname><given-names>R.C.</given-names></name><name><surname>Jobin</surname><given-names>C.</given-names></name></person-group><article-title>Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer</article-title><source>Nat. Cancer</source><year>2020</year><volume>1</volume><fpage>723</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-0078-7</pub-id><pub-id pub-id-type="pmid">33768208</pub-id></element-citation></ref><ref id="B47-toxins-13-00346"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>J.-U.</given-names></name><name><surname>Gray</surname><given-names>M.J.</given-names></name><name><surname>Bazopoulou</surname><given-names>D.</given-names></name><name><surname>Beaufay</surname><given-names>F.</given-names></name><name><surname>Lempart</surname><given-names>J.</given-names></name><name><surname>Koenigsknecht</surname><given-names>M.J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Baker</surname><given-names>J.R.</given-names></name><name><surname>Hasler</surname><given-names>W.L.</given-names></name><name><surname>Young</surname><given-names>V.B.</given-names></name><etal/></person-group><article-title>The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation</article-title><source>Nat. Microbiol.</source><year>2017</year><volume>2</volume><fpage>16267</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.267</pub-id><pub-id pub-id-type="pmid">28112760</pub-id></element-citation></ref><ref id="B48-toxins-13-00346"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang-Fichaux</surname><given-names>M.</given-names></name><name><surname>Chagneau</surname><given-names>C.V.</given-names></name><name><surname>Bossuet-Greif</surname><given-names>N.</given-names></name><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name><name><surname>Oswald</surname><given-names>&#x000c9;.</given-names></name><name><surname>Branchu</surname><given-names>P.</given-names></name></person-group><article-title>The Polyphosphate Kinase of <italic>Escherichia coli</italic> Is Required for Full Production of the Genotoxin Colibactin</article-title><source>mSphere</source><year>2020</year><volume>5</volume><fpage>e01195-20</fpage><pub-id pub-id-type="doi">10.1128/mSphere.01195-20</pub-id><?supplied-pmid 33328353?><pub-id pub-id-type="pmid">33328353</pub-id></element-citation></ref><ref id="B49-toxins-13-00346"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumych</surname><given-names>T.</given-names></name><name><surname>Yamakawa</surname><given-names>N.</given-names></name><name><surname>Sivignon</surname><given-names>A.</given-names></name><name><surname>Garenaux</surname><given-names>E.</given-names></name><name><surname>Robakiewicz</surname><given-names>S.</given-names></name><name><surname>Coddeville</surname><given-names>B.</given-names></name><name><surname>Bongiovanni</surname><given-names>A.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Barnich</surname><given-names>N.</given-names></name><name><surname>Szunerits</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Oligomannose-Rich Membranes of Dying Intestinal Epithelial Cells Promote Host Colonization by Adherent-Invasive <italic>E. coli</italic></article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>742</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.00742</pub-id><pub-id pub-id-type="pmid">29720971</pub-id></element-citation></ref><ref id="B50-toxins-13-00346"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddocks</surname><given-names>O.D.K.</given-names></name><name><surname>Short</surname><given-names>A.J.</given-names></name><name><surname>Donnenberg</surname><given-names>M.S.</given-names></name><name><surname>Bader</surname><given-names>S.</given-names></name><name><surname>Harrison</surname><given-names>D.J.</given-names></name></person-group><article-title>Attaching and effacing <italic>Escherichia coli</italic> downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e5517</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005517</pub-id><pub-id pub-id-type="pmid">19436735</pub-id></element-citation></ref><ref id="B51-toxins-13-00346"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>H.M.</given-names></name><name><surname>Campbell</surname><given-names>B.J.</given-names></name><name><surname>Hart</surname><given-names>C.A.</given-names></name><name><surname>Mpofu</surname><given-names>C.</given-names></name><name><surname>Nayar</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Englyst</surname><given-names>H.</given-names></name><name><surname>Williams</surname><given-names>H.F.</given-names></name><name><surname>Rhodes</surname><given-names>J.M.</given-names></name></person-group><article-title>Enhanced <italic>Escherichia coli</italic> adherence and invasion in Crohn&#x02019;s disease and colon cancer</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.03.054</pub-id><?supplied-pmid 15236175?><pub-id pub-id-type="pmid">15236175</pub-id></element-citation></ref><ref id="B52-toxins-13-00346"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>C.</given-names></name><name><surname>Alzheimer</surname><given-names>M.</given-names></name><name><surname>Walles</surname><given-names>H.</given-names></name><name><surname>Oelschlaeger</surname><given-names>T.A.</given-names></name></person-group><article-title>An adherent mucus layer attenuates the genotoxic effect of colibactin</article-title><source>Cell Microbiol.</source><year>2018</year><volume>20</volume><fpage>12812</fpage><pub-id pub-id-type="doi">10.1111/cmi.12812</pub-id></element-citation></ref><ref id="B53-toxins-13-00346"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanin</surname><given-names>R.B.</given-names></name><name><surname>Winter</surname><given-names>M.G.</given-names></name><name><surname>Spiga</surname><given-names>L.</given-names></name><name><surname>Hughes</surname><given-names>E.R.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Taylor</surname><given-names>S.J.</given-names></name><name><surname>Arenales</surname><given-names>A.</given-names></name><name><surname>Gillis</surname><given-names>C.C.</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>L.</given-names></name><name><surname>Jimenez</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Epithelial-Derived Reactive Oxygen Species Enable AppBCX-Mediated Aerobic Respiration of <italic>Escherichia coli</italic> during Intestinal Inflammation</article-title><source>Cell Host Microbe</source><year>2020</year><volume>28</volume><fpage>780</fpage><lpage>788.e5</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.09.005</pub-id><pub-id pub-id-type="pmid">33053375</pub-id></element-citation></ref><ref id="B54-toxins-13-00346"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>S.E.</given-names></name><name><surname>Winter</surname><given-names>M.G.</given-names></name><name><surname>Xavier</surname><given-names>M.N.</given-names></name><name><surname>Thiennimitr</surname><given-names>P.</given-names></name><name><surname>Poon</surname><given-names>V.</given-names></name><name><surname>Keestra</surname><given-names>A.M.</given-names></name><name><surname>Laughlin</surname><given-names>R.C.</given-names></name><name><surname>Gomez</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Lawhon</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Host-derived nitrate boosts growth of E. coli in the inflamed gut</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>708</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1126/science.1232467</pub-id><pub-id pub-id-type="pmid">23393266</pub-id></element-citation></ref><ref id="B55-toxins-13-00346"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tytgat</surname><given-names>H.L.P.</given-names></name><name><surname>Nobrega</surname><given-names>F.L.</given-names></name><name><surname>van der Oost</surname><given-names>J.</given-names></name><name><surname>de Vos</surname><given-names>W.M.</given-names></name></person-group><article-title>Bowel Biofilms: Tipping Points between a Healthy and Compromised Gut?</article-title><source>Trends Microbiol.</source><year>2019</year><volume>27</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.08.009</pub-id><pub-id pub-id-type="pmid">30219265</pub-id></element-citation></ref><ref id="B56-toxins-13-00346"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motta</surname><given-names>J.-P.</given-names></name><name><surname>Allain</surname><given-names>T.</given-names></name><name><surname>Green-Harrison</surname><given-names>L.E.</given-names></name><name><surname>Groves</surname><given-names>R.A.</given-names></name><name><surname>Feener</surname><given-names>T.</given-names></name><name><surname>Ramay</surname><given-names>H.</given-names></name><name><surname>Beck</surname><given-names>P.L.</given-names></name><name><surname>Lewis</surname><given-names>I.A.</given-names></name><name><surname>Wallace</surname><given-names>J.L.</given-names></name><name><surname>Buret</surname><given-names>A.G.</given-names></name></person-group><article-title>Iron sequestration in microbiota biofilms as A novel strategy for treating inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2018</year><volume>24</volume><fpage>1493</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1093/ibd/izy116</pub-id><?supplied-pmid 29788224?><pub-id pub-id-type="pmid">29788224</pub-id></element-citation></ref><ref id="B57-toxins-13-00346"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejea</surname><given-names>C.M.</given-names></name><name><surname>Wick</surname><given-names>E.C.</given-names></name><name><surname>Hechenbleikner</surname><given-names>E.M.</given-names></name><name><surname>White</surname><given-names>J.R.</given-names></name><name><surname>Mark Welch</surname><given-names>J.L.</given-names></name><name><surname>Rossetti</surname><given-names>B.J.</given-names></name><name><surname>Peterson</surname><given-names>S.N.</given-names></name><name><surname>Snesrud</surname><given-names>E.C.</given-names></name><name><surname>Borisy</surname><given-names>G.G.</given-names></name><name><surname>Lazarev</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Microbiota organization is a distinct feature of proximal colorectal cancers</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>18321</fpage><lpage>18326</lpage><pub-id pub-id-type="doi">10.1073/pnas.1406199111</pub-id><pub-id pub-id-type="pmid">25489084</pub-id></element-citation></ref><ref id="B58-toxins-13-00346"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejea</surname><given-names>C.M.</given-names></name><name><surname>Fathi</surname><given-names>P.</given-names></name><name><surname>Craig</surname><given-names>J.M.</given-names></name><name><surname>Boleij</surname><given-names>A.</given-names></name><name><surname>Taddese</surname><given-names>R.</given-names></name><name><surname>Geis</surname><given-names>A.L.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>DeStefano Shields</surname><given-names>C.E.</given-names></name><name><surname>Hechenbleikner</surname><given-names>E.M.</given-names></name><name><surname>Huso</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1126/science.aah3648</pub-id><?supplied-pmid 29420293?><pub-id pub-id-type="pmid">29420293</pub-id></element-citation></ref><ref id="B59-toxins-13-00346"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drewes</surname><given-names>J.L.</given-names></name><name><surname>White</surname><given-names>J.R.</given-names></name><name><surname>Dejea</surname><given-names>C.M.</given-names></name><name><surname>Fathi</surname><given-names>P.</given-names></name><name><surname>Iyadorai</surname><given-names>T.</given-names></name><name><surname>Vadivelu</surname><given-names>J.</given-names></name><name><surname>Roslani</surname><given-names>A.C.</given-names></name><name><surname>Wick</surname><given-names>E.C.</given-names></name><name><surname>Mongodin</surname><given-names>E.F.</given-names></name><name><surname>Loke</surname><given-names>M.F.</given-names></name><etal/></person-group><article-title>High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia</article-title><source>NPJ Biofilms Microb.</source><year>2017</year><volume>3</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1038/s41522-017-0040-3</pub-id></element-citation></ref><ref id="B60-toxins-13-00346"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomkovich</surname><given-names>S.</given-names></name><name><surname>Dejea</surname><given-names>C.M.</given-names></name><name><surname>Winglee</surname><given-names>K.</given-names></name><name><surname>Drewes</surname><given-names>J.L.</given-names></name><name><surname>Chung</surname><given-names>L.</given-names></name><name><surname>Housseau</surname><given-names>F.</given-names></name><name><surname>Pope</surname><given-names>J.L.</given-names></name><name><surname>Gauthier</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>M&#x000fc;hlbauer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic</article-title><source>J. Clin. Investig.</source><year>2019</year><volume>129</volume><fpage>1699</fpage><lpage>1712</lpage><pub-id pub-id-type="doi">10.1172/JCI124196</pub-id><?supplied-pmid 30855275?><pub-id pub-id-type="pmid">30855275</pub-id></element-citation></ref><ref id="B61-toxins-13-00346"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomkovich</surname><given-names>S.</given-names></name><name><surname>Jobin</surname><given-names>C.</given-names></name></person-group><article-title>Microbial networking in cancer: When two toxins collide</article-title><source>Br. J. Cancer</source><year>2018</year><volume>118</volume><fpage>1407</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1038/s41416-018-0101-2</pub-id><pub-id pub-id-type="pmid">29773837</pub-id></element-citation></ref><ref id="B62-toxins-13-00346"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalmasso</surname><given-names>G.</given-names></name><name><surname>Cougnoux</surname><given-names>A.</given-names></name><name><surname>Delmas</surname><given-names>J.</given-names></name><name><surname>Darfeuille-Michaud</surname><given-names>A.</given-names></name><name><surname>Bonnet</surname><given-names>R.</given-names></name></person-group><article-title>The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment</article-title><source>Gut Microbes</source><year>2014</year><volume>5</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.4161/19490976.2014.969989</pub-id><pub-id pub-id-type="pmid">25483338</pub-id></element-citation></ref><ref id="B63-toxins-13-00346"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cougnoux</surname><given-names>A.</given-names></name><name><surname>Dalmasso</surname><given-names>G.</given-names></name><name><surname>Martinez</surname><given-names>R.</given-names></name><name><surname>Buc</surname><given-names>E.</given-names></name><name><surname>Delmas</surname><given-names>J.</given-names></name><name><surname>Gibold</surname><given-names>L.</given-names></name><name><surname>Sauvanet</surname><given-names>P.</given-names></name><name><surname>Darcha</surname><given-names>C.</given-names></name><name><surname>D&#x000e9;chelotte</surname><given-names>P.</given-names></name><name><surname>Bonnet</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype</article-title><source>Gut</source><year>2014</year><volume>63</volume><fpage>1932</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2013-305257</pub-id><pub-id pub-id-type="pmid">24658599</pub-id></element-citation></ref><ref id="B64-toxins-13-00346"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lop&#x000e8;s</surname><given-names>A.</given-names></name><name><surname>Billard</surname><given-names>E.</given-names></name><name><surname>Casse</surname><given-names>A.H.</given-names></name><name><surname>Vill&#x000e9;ger</surname><given-names>R.</given-names></name><name><surname>Veziant</surname><given-names>J.</given-names></name><name><surname>Roche</surname><given-names>G.</given-names></name><name><surname>Carrier</surname><given-names>G.</given-names></name><name><surname>Sauvanet</surname><given-names>P.</given-names></name><name><surname>Briat</surname><given-names>A.</given-names></name><name><surname>Pag&#x000e8;s</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Colibactin-positive <italic>Escherichia coli</italic> induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer</article-title><source>Int. J. Cancer</source><year>2020</year><volume>146</volume><fpage>3147</fpage><lpage>3159</lpage><pub-id pub-id-type="doi">10.1002/ijc.32920</pub-id><pub-id pub-id-type="pmid">32037530</pub-id></element-citation></ref><ref id="B65-toxins-13-00346"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>C.</given-names></name><name><surname>Coyte</surname><given-names>K.Z.</given-names></name><name><surname>Bainter</surname><given-names>W.</given-names></name><name><surname>Geha</surname><given-names>R.S.</given-names></name><name><surname>Martin</surname><given-names>C.R.</given-names></name><name><surname>Rakoff-Nahoum</surname><given-names>S.</given-names></name></person-group><article-title>Multi-kingdom ecological drivers of microbiota assembly in preterm infants</article-title><source>Nature</source><year>2021</year><volume>591</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03241-8</pub-id><pub-id pub-id-type="pmid">33627867</pub-id></element-citation></ref><ref id="B66-toxins-13-00346"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizcaino</surname><given-names>M.I.</given-names></name><name><surname>Engel</surname><given-names>P.</given-names></name><name><surname>Trautman</surname><given-names>E.</given-names></name><name><surname>Crawford</surname><given-names>J.M.</given-names></name></person-group><article-title>Comparative metabolomics and structural characterizations illuminate colibactin pathway-dependent small molecules</article-title><source>J. Am. Chem. Soc.</source><year>2014</year><volume>136</volume><fpage>9244</fpage><lpage>9247</lpage><pub-id pub-id-type="doi">10.1021/ja503450q</pub-id><pub-id pub-id-type="pmid">24932672</pub-id></element-citation></ref><ref id="B67-toxins-13-00346"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tronnet</surname><given-names>S.</given-names></name><name><surname>Floch</surname><given-names>P.</given-names></name><name><surname>Lucarelli</surname><given-names>L.</given-names></name><name><surname>Gaillard</surname><given-names>D.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name><name><surname>Serino</surname><given-names>M.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name></person-group><article-title>The genotoxin colibactin shapes gut microbiota in mice</article-title><source>mSphere</source><year>2020</year><volume>5</volume><fpage>e00589-20</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00589-20</pub-id><?supplied-pmid 32611705?><pub-id pub-id-type="pmid">32611705</pub-id></element-citation></ref><ref id="B68-toxins-13-00346"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Raes</surname><given-names>J.</given-names></name><name><surname>Arumugam</surname><given-names>M.</given-names></name><name><surname>Burgdorf</surname><given-names>K.S.</given-names></name><name><surname>Manichanh</surname><given-names>C.</given-names></name><name><surname>Nielsen</surname><given-names>T.</given-names></name><name><surname>Pons</surname><given-names>N.</given-names></name><name><surname>Levenez</surname><given-names>F.</given-names></name><name><surname>Yamada</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A human gut microbial gene catalogue established by metagenomic sequencing</article-title><source>Nature</source><year>2010</year><volume>464</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nature08821</pub-id><?supplied-pmid 20203603?><pub-id pub-id-type="pmid">20203603</pub-id></element-citation></ref><ref id="B69-toxins-13-00346"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magne</surname><given-names>F.</given-names></name><name><surname>Gotteland</surname><given-names>M.</given-names></name><name><surname>Gauthier</surname><given-names>L.</given-names></name><name><surname>Zazueta</surname><given-names>A.</given-names></name><name><surname>Pesoa</surname><given-names>S.</given-names></name><name><surname>Navarrete</surname><given-names>P.</given-names></name><name><surname>Balamurugan</surname><given-names>R.</given-names></name></person-group><article-title>The firmicutes/bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients?</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>1474</elocation-id><pub-id pub-id-type="doi">10.3390/nu12051474</pub-id></element-citation></ref><ref id="B70-toxins-13-00346"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Cheuk-Hay Lau</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Jao-Yiu Sung</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis</article-title><source>Gastroenterology</source><year>2021</year><pub-id pub-id-type="doi">10.1053/j.gastro.2021.02.020</pub-id></element-citation></ref><ref id="B71-toxins-13-00346"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwabe</surname><given-names>R.F.</given-names></name><name><surname>Jobin</surname><given-names>C.</given-names></name></person-group><article-title>The microbiome and cancer</article-title><source>Nat. Rev. Cancer</source><year>2013</year><volume>13</volume><fpage>800</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/nrc3610</pub-id><?supplied-pmid 24132111?><pub-id pub-id-type="pmid">24132111</pub-id></element-citation></ref><ref id="B72-toxins-13-00346"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>R.M.</given-names></name><name><surname>Jobin</surname><given-names>C.</given-names></name></person-group><article-title>Microbiota in pancreatic health and disease: The next frontier in microbiome research</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2020</year><volume>17</volume><fpage>53</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/s41575-019-0242-7</pub-id><?supplied-pmid 31811279?><pub-id pub-id-type="pmid">31811279</pub-id></element-citation></ref><ref id="B73-toxins-13-00346"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>M.</given-names></name></person-group><article-title>Clinical use of E. coli Nissle 1917 in inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2008</year><volume>14</volume><fpage>1012</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1002/ibd.20377</pub-id><?supplied-pmid 18240278?><pub-id pub-id-type="pmid">18240278</pub-id></element-citation></ref><ref id="B74-toxins-13-00346"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubbert</surname><given-names>S.</given-names></name><name><surname>Klinkert</surname><given-names>B.</given-names></name><name><surname>Schimiczek</surname><given-names>M.</given-names></name><name><surname>Wassenaar</surname><given-names>T.M.</given-names></name><name><surname>von B&#x000fc;nau</surname><given-names>R.</given-names></name></person-group><article-title>No Genotoxicity Is Detectable for <italic>Escherichia coli</italic> Strain Nissle 1917 by Standard In Vitro and In Vivo Tests</article-title><source>Eur. J. Microbiol. Immunol.</source><year>2020</year><volume>10</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1556/1886.2019.00025</pub-id></element-citation></ref><ref id="B75-toxins-13-00346"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chagneau</surname><given-names>C.V.</given-names></name><name><surname>Massip</surname><given-names>C.</given-names></name><name><surname>Bossuet-Greif</surname><given-names>N.</given-names></name><name><surname>Fremez</surname><given-names>C.</given-names></name><name><surname>Motta</surname><given-names>J.-P.</given-names></name><name><surname>Shima</surname><given-names>A.</given-names></name><name><surname>Besson</surname><given-names>C.</given-names></name><name><surname>Le Faouder</surname><given-names>P.</given-names></name><name><surname>C&#x000e9;nac</surname><given-names>N.</given-names></name><name><surname>Roth</surname><given-names>M.-P.</given-names></name><etal/></person-group><article-title>coli induces DNA damage in the bladder</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><elocation-id>e1009310</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009310</pub-id><pub-id pub-id-type="pmid">33630958</pub-id></element-citation></ref><ref id="B76-toxins-13-00346"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>E.</given-names></name><name><surname>Coulter</surname><given-names>J.B.</given-names></name><name><surname>Guzman</surname><given-names>W.</given-names></name><name><surname>Ozbek</surname><given-names>B.</given-names></name><name><surname>Mummert</surname><given-names>L.</given-names></name><name><surname>Ernst</surname><given-names>S.E.</given-names></name><name><surname>Maynard</surname><given-names>J.P.</given-names></name><name><surname>Meeker</surname><given-names>A.K.</given-names></name><name><surname>Heaphy</surname><given-names>C.M.</given-names></name><name><surname>Haffner</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Oncogenic Gene Fusions in Non-Neoplastic Precursors as Evidence that Bacterial Infection Initiates Prostate Cancer</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.07.27.224154</pub-id></element-citation></ref><ref id="B77-toxins-13-00346"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohrhunter</surname><given-names>J.</given-names></name><name><surname>Taffner</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Hardy</surname><given-names>D.</given-names></name><name><surname>Pecora</surname><given-names>N.</given-names></name></person-group><article-title>Genomic Characterization of Tissue Invasive <italic>Klebsiella pneumoniae</italic> Complex in a Hospital System with a Focus on Species Distribution and Hypervirulence</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.11.04.369173</pub-id></element-citation></ref><ref id="B78-toxins-13-00346"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balskus</surname><given-names>E.P.</given-names></name></person-group><article-title>Colibactin: Understanding an elusive gut bacterial genotoxin</article-title><source>Nat. Prod. Rep.</source><year>2015</year><volume>32</volume><fpage>1534</fpage><lpage>1540</lpage><pub-id pub-id-type="doi">10.1039/C5NP00091B</pub-id><?supplied-pmid 26390983?><pub-id pub-id-type="pmid">26390983</pub-id></element-citation></ref><ref id="B79-toxins-13-00346"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kronheim</surname><given-names>S.</given-names></name><name><surname>Daniel-Ivad</surname><given-names>M.</given-names></name><name><surname>Duan</surname><given-names>Z.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>A.I.</given-names></name><name><surname>Mantel</surname><given-names>I.</given-names></name><name><surname>Nodwell</surname><given-names>J.R.</given-names></name><name><surname>Maxwell</surname><given-names>K.L.</given-names></name></person-group><article-title>A chemical defence against phage infection</article-title><source>Nature</source><year>2018</year><volume>564</volume><fpage>283</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0767-x</pub-id><?supplied-pmid 30518855?><pub-id pub-id-type="pmid">30518855</pub-id></element-citation></ref><ref id="B80-toxins-13-00346"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>B.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Sanchez</surname><given-names>C.</given-names></name><name><surname>Edwards</surname><given-names>D.J.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Murrell</surname><given-names>J.M.</given-names></name></person-group><article-title>The biosynthetic gene cluster for the anticancer drug bleomycin from Streptomyces verticillus ATCC15003 as a model for hybrid peptide-polyketide natural product biosynthesis</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2001</year><volume>27</volume><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/sj.jim.7000194</pub-id><pub-id pub-id-type="pmid">11774003</pub-id></element-citation></ref><ref id="B81-toxins-13-00346"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Secher</surname><given-names>T.</given-names></name><name><surname>Brehin</surname><given-names>C.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name></person-group><article-title>Early settlers: Which <italic>E. coli</italic> strains do you not want at birth?</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2016</year><volume>311</volume><fpage>G123</fpage><lpage>G129</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00091.2016</pub-id><?supplied-pmid 27288422?><pub-id pub-id-type="pmid">27288422</pub-id></element-citation></ref><ref id="B82-toxins-13-00346"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>G.</given-names></name><name><surname>Bikard</surname><given-names>D.</given-names></name></person-group><article-title>Editing the microbiome the CRISPR way</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2019</year><volume>374</volume><fpage>20180103</fpage><pub-id pub-id-type="doi">10.1098/rstb.2018.0103</pub-id><?supplied-pmid 30905295?><pub-id pub-id-type="pmid">30905295</pub-id></element-citation></ref><ref id="B83-toxins-13-00346"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>P.</given-names></name><name><surname>Shine</surname><given-names>E.E.</given-names></name><name><surname>Healy</surname><given-names>A.R.</given-names></name><name><surname>Kim</surname><given-names>C.S.</given-names></name><name><surname>Herzon</surname><given-names>S.B.</given-names></name><name><surname>Bruner</surname><given-names>S.D.</given-names></name><name><surname>Crawford</surname><given-names>J.M.</given-names></name></person-group><article-title>Clbs is a cyclopropane hydrolase that confers colibactin resistance</article-title><source>J. Am. Chem. Soc.</source><year>2017</year><volume>139</volume><fpage>17719</fpage><lpage>17722</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b09971</pub-id><pub-id pub-id-type="pmid">29112397</pub-id></element-citation></ref><ref id="B84-toxins-13-00346"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossuet-Greif</surname><given-names>N.</given-names></name><name><surname>Dubois</surname><given-names>D.</given-names></name><name><surname>Petit</surname><given-names>C.</given-names></name><name><surname>Tronnet</surname><given-names>S.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name><name><surname>Bonnet</surname><given-names>R.</given-names></name><name><surname>Oswald</surname><given-names>E.</given-names></name><name><surname>Nougayr&#x000e8;de</surname><given-names>J.-P.</given-names></name></person-group><article-title><italic>Escherichia coli</italic>&#x02005;ClbS is a colibactin resistance protein</article-title><source>Mol. Microbiol.</source><year>2016</year><volume>99</volume><fpage>897</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1111/mmi.13272</pub-id><?supplied-pmid 26560421?><pub-id pub-id-type="pmid">26560421</pub-id></element-citation></ref><ref id="B85-toxins-13-00346"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Divya Ganeshan</surname><given-names>S.</given-names></name><name><surname>Hosseinidoust</surname><given-names>Z.</given-names></name></person-group><article-title>Phage Therapy with a Focus on the Human Microbiota</article-title><source>Antibiotics</source><year>2019</year><volume>8</volume><elocation-id>131</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics8030131</pub-id></element-citation></ref><ref id="B86-toxins-13-00346"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gogokhia</surname><given-names>L.</given-names></name><name><surname>Buhrke</surname><given-names>K.</given-names></name><name><surname>Bell</surname><given-names>R.</given-names></name><name><surname>Hoffman</surname><given-names>B.</given-names></name><name><surname>Brown</surname><given-names>D.G.</given-names></name><name><surname>Hanke-Gogokhia</surname><given-names>C.</given-names></name><name><surname>Ajami</surname><given-names>N.J.</given-names></name><name><surname>Wong</surname><given-names>M.C.</given-names></name><name><surname>Ghazaryan</surname><given-names>A.</given-names></name><name><surname>Valentine</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis</article-title><source>Cell. Host Microbe</source><year>2019</year><volume>25</volume><fpage>285</fpage><lpage>299.e8</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.01.008</pub-id><pub-id pub-id-type="pmid">30763538</pub-id></element-citation></ref><ref id="B87-toxins-13-00346"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonfiglio</surname><given-names>G.</given-names></name><name><surname>Neroni</surname><given-names>B.</given-names></name><name><surname>Radocchia</surname><given-names>G.</given-names></name><name><surname>Pompilio</surname><given-names>A.</given-names></name><name><surname>Mura</surname><given-names>F.</given-names></name><name><surname>Trancassini</surname><given-names>M.</given-names></name><name><surname>Di Bonaventura</surname><given-names>G.</given-names></name><name><surname>Pantanella</surname><given-names>F.</given-names></name><name><surname>Schippa</surname><given-names>S.</given-names></name></person-group><article-title>Growth Control of Adherent-Invasive <italic>Escherichia coli</italic> (AIEC) by the Predator Bacteria Bdellovibrio bacteriovorus: A New Therapeutic Approach for Crohn&#x02019;s Disease Patients</article-title><source>Microorganisms</source><year>2019</year><volume>8</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8010017</pub-id><?supplied-pmid 31861852?><pub-id pub-id-type="pmid">31861852</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="toxins-13-00346-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Colibactin is a product of the 54-kb <italic>pks</italic> gene island. The <italic>pks</italic> gene island consists of 19 <italic>clb</italic> genes transcribed in four polycistronic and three cistronic elements, encoding various non-ribosomal peptide synthetase (NRPS), polyketide synthetase (PKS), hybrid NRPS-PKS or accessory proteins. Colibactin production is regulated by the LuxR-type transcriptional activator ClbR and the pantetheinyltransferase (PPTase) ClbA. Following transcriptional activation, a biosynthetic scaffold coordinates production of a linear intermediate (precolibactin) harboring a <italic>N</italic>-myristoyl-D-Asn motif. The transmembrane peptidase ClbP removes these prodrug motifs, inducing spontaneous dual two-fold cyclizing events resulting in production of the bioactive colibactin molecule, characterized by two electrophilic cyclopropane warheads with high binding-affinity for adenine residues within AAWWTT nucleotide motifs.</p></caption><graphic xlink:href="toxins-13-00346-g001"/></fig><fig id="toxins-13-00346-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><italic>Pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> promote tumor formation in the colonic epithelium. During infection with <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic>, colibactin molecules translocate to the host nucleus via an undetermined mechanism, where the compound generates inter-strand crosslinks (ICLs) in adenine-rich nucleotide motifs and double-strand DNA breaks (DSBs). Errors during DNA repair following <italic>pks</italic>-induced damage result in the accumulation of a specific mutational signature characterized by T &#x0003e; N single base substitutions (SBS<sub>pks</sub>) or insertion/deletions of varying length (ID<sub>pks</sub>). Exposure to <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> induces oncogenic phenotypes characterized by enhanced proliferation and <italic>Wnt</italic> independence. Unrepaired lesions cause cell-cycle arrest. Arrested cells adopt a senescence-associated secretory phenotype (SASP) resulting in enhanced growth factor production (hepatocyte growth factor [HGF], fibroblast growth factor [FGF]) which promote proliferation of nearby cells.</p></caption><graphic xlink:href="toxins-13-00346-g002"/></fig><fig id="toxins-13-00346-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Transcriptional regulation of <italic>clb</italic> genes. (<bold>A</bold>) Transcription of the regulatory <italic>clb</italic> genes (<italic>clbA</italic> and <italic>clbR</italic>) is increased in low-iron or oligosaccharide rich environments. The endo- or exogenously derived polyamine spermidine is necessary for <italic>pks</italic> transcription. (<bold>B</bold>) Inflammation promotes the transcription of several individual <italic>clb</italic> components. Administration of anti-inflammatory drugs such as anti-TNF attenuate these effects and limit <italic>pks</italic>-associated tumorigenicity <italic>in vivo</italic>. Anti-polyphosphate kinase (PPK) inhibitors downregulate <italic>clbB</italic> expression and the genotoxicity of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic>.</p></caption><graphic xlink:href="toxins-13-00346-g003"/></fig><fig id="toxins-13-00346-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The oncogenic capacity of <italic>pks</italic><sup>+</sup>&#x000a0;<italic>Escherichia coli</italic> is enhanced by increased mucosal invasion and biofilm association. In healthy tissue, <italic>E. coli</italic> typically aggregate at the mucosal surface. In biofilm-covered CRCs, <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic> form biofilms in cooperation with enterotoxigenic <italic>Bacteroides fragilis</italic> (ETBF), increasing depth of mucosal invasion. During inflammation, a microaerobic niche formed within the mucosa (derived from host nitric oxides or peroxides) facilitates the expansion of mucosal <italic>E. coli</italic> populations.</p></caption><graphic xlink:href="toxins-13-00346-g004"/></fig><fig id="toxins-13-00346-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Future areas of research involving <italic>pks</italic><sup>+</sup>&#x000a0;<italic>E. coli</italic>.</p></caption><graphic xlink:href="toxins-13-00346-g005"/></fig></floats-group></article>